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Dengue virus (DENV) infection is the most prevalent arthropod-borne virus 
disease. There are estimated 100 million symptomatic cases of dengue disease per year 
worldwide. A lack of effective antiviral therapies or vaccines makes DENV infections 
a major global health concern. Therefore, understanding the viral and host factors 
contributing to the disease pathogenesis is critical. DENV has been shown to 
effectively counteract host innate immune mechanisms. In particular, DENV protease, 
NS3 has emerged as an inhibitor of host cellular signaling by targeting crucial host 
proteins.  Here we identified RIPK1 as a novel target of DENV NS3. RIPK1 is a 
central mediator of innate immune regulation downstream of TNFR1, TLR3, TLR4, 
RIG-I, and MDA-5. The outcomes of RIPK1-mediated inflammatory signaling include 
NF-kB and MAPK activation and IRF3/IRF7 phosphorylation. RIPK1 also regulates 
cell death signaling by modulating extrinsic apoptosis and necroptosis. 
 We observed that RIPK1 levels were significantly decreased in numerous cell 
types with DENV infection. DENV NS3 was responsible for decreased RIPK1 levels 
as shown by overexpression experiments. NS3 protease activity was fundamental for 
this effect, because the overexpression of a catalytically inactive protease mutant 
(NS2B3-S135A) did not result in a significant RIPK1 reduction. Additionally, both 
wild type and protease mutant NS3 physically interacted with RIPK1 as shown by co-
immunoprecipitation experiments. Consequently, DENV inhibited NF-kB activation 
downstream of TNFR1 and TLR3 receptors by targeting RIPK1. Furthermore, we 
detected that DENV did not induce necroptosis and further suppressed TNFR1-
 
induced necroptosis. Our findings add RIPK1 to the list of host proteins targeted by 
DENV NS3 and expand the knowledge of strategies used by DENV to evade innate 
immune responses. Manipulation of host cell RIPK1 signaling by DENV may 
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            The following dissertation has been prepared in manuscript format according 
to the guidelines of the Graduate School of the University of Rhode Island. The 
dissertation includes five chapters: Chapter 1, Introduction. Chapter 2, “Virus 
inhibition of RIPK1-mediated innate immune signaling” prepared for submission to 
mBio. Chapter 3, “Dengue virus downregulates TNFR1- and TLR3-stimulated NF-𝛋B 
activation by targeting RIPK1” was prepared for submission to PLOS PATHOGENS. 
Chapter 4, “Additional mechanisms and implications of RIPK1 downregulation by 
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 Dengue virus (DENV) infection, the most prevalent arthropod-borne virus 
disease, represents a major global human health concern. DENV is endemic to more 
than 100 countries in the world (Fig 1). Three billion people in tropical and subtropical 
regions in the world are at a higher risk of getting infected with DENV. Approximately 
50-100 million people are reported to exhibit symptoms due to DENV infections, 
annually. The majority of infected individuals develop a mild febrile illness, but 
approximately 500,000 clinical cases result in more severe dengue hemorrhagic fever/ 
dengue shock syndrome leading to 25-50,000 deaths per year (1,2) . Significantly, the 
incidence has increased 30-fold in the last 50 years due to accelerating geographical 
spread of the virus. This is evidenced by the identification of new cases of dengue 
fever in Florida (USA), France, Spain and Japan in higher latitude regions (3,4). 
 The primary vector of the DENV is a female Aedes aegypti mosquito. These 
mosquitos feed on the blood of humans primarily during the daytime. A. aegypti get 
the virus after biting an infected individual. Following 8-10 days of virus incubation, 
an infected mosquito is capable of disseminating the virus to susceptible individuals 
























DENV infections are caused by four closely related serotypes (DENV 1, 2, 3, 4). 
Immune responses following primary DENV infection fully protect against the DENV 
serotype that caused the primary infection,  but only partially, and transiently, protect 
against heterologous serotypes (6). DENV infection may result in asymptomatic or 
symptomatic manifestations. Symptomatic cases constitute ~20% of infections. 
Symptomatic infections result in a broad spectrum of effects including febrile illness , 
which may be uncomplicated (dengue fever, DF) or progress to a potentially fatal 
disease, such as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) 
(7,8). DF is a mild “flu-like” illness, which could appear 3-10 days after virus 
infection via a mosquito bite. Other symptoms associated with DF are retro-orbital 
pain, intense headache, intense joint and muscle pain and nausea (9,10).  Even though 
a majority of patients are able to recover completely after the febrile phase, some 
(~3%) develop severe disease. DHF is distinguished from DF by the appearance of 
vascular permeability, plasma leakage and bleeding manifestations. Thrombocytopenia 
and coagulopathy are also associated with severe disease. Severe plasma leakage can 
result in hypovolemic shock (4). These symptoms may lead to organ impairment and 
death of the patient. DHF is often associated with hepatomegaly and histopathological 
reports of human fatal dengue cases indicate that the liver, spleen and lymph nodes are 





Factors contributing to Dengue Disease pathogenesis 
            Various factors are considered to contribute to the dengue disease severity. For 
example, virus virulence, preexisting dengue antibodies, immune dysregulation and 
host genetic susceptibility are factors known to be associated with dengue 
pathogenesis. Paradoxically, severe dengue symptoms (e.g., plasma leakage) are not 
observed when the viremia is at the highest, but when the virus is being cleared, 
suggesting that host immune responses play an adverse role in disease pathogenesis 
(12). Some of the components that are known to contribute to dengue pathogenesis are 
discussed below.  
 
1. Antibody-dependent enhancement 
             Multiple  cohort studies have identified secondary DENV infection as an 
epidemiological risk factor for severe dengue (13–15). However, a majority of tertiary 
and quaternary infections are clinically silent or mild (16).  A potential reason for 
increased risk with the secondary infection is the presence of non-neutralizing, cross-
reactive antibodies generated against the primary infection. These antibodies bind the 
second virus (heterologous serotype) and facilitate infection via Fc𝛾 receptors 
expressed on cell surfaces. This phenomenon is known as “Antibody-dependent 
enhancement (ADE)” (Fig 2). Thus, increased numbers of virus-infected cells due to 
ADE may increase disease pathogenesis in secondary infection (17,18). The only 
licensed vaccine against dengue, Dengvaxia, increased the risk of severe disease in 
children when they were subsequently infected by DENV. The vaccination itself acted 
as a primary infection inducing antibody production, which enhanced virus infection 
 5 
in the event of a secondary infection, perhaps via ADE (19). 
 
 
Figure 2. The mechanism of Antibody-Dependent Enhancement 
(Adapted from Puccionoi-Sohler et al., 2015) 
 
2. T cell mediated immunity 
 
            T cell mediated immune responses during the secondary infection have been 
proposed to contribute to the severity of dengue disease (18). Virus-specific CD8+ 
cytotoxic T lymphocytes (CTL) directly lyse virus-infected antigen-presenting cells 
(APC). Additionally, CTL secrete cytokines such as IFN𝛾, which enhances 
cytotoxicity of CTLs and increases their motility (20). Other cytokines secreted by T 
cells, such as IL-8 and IL-9, stimulate recruitment and activation of other immune 
cells. Thus, T cells are important for controlling DENV infections. However, with the 
encounter of a secondary DENV infection there is a tendency toward expansion of the 
memory T cell repertoire from the previous infection. These T cells may exhibit a 
lower avidity to the current serotype and induce “skewed” immune responses, which 
could be deleterious to the host (18). These responses may result in an altered cytokine 
profile which could exacerbate the disease. This is evidenced by the detection of 
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increased T cell activation in DHF than in DF patients. Patients experiencing severe 
dengue have altered cytokine profiles as compared to patients exhibiting milder 
disease (21).  Taken together, these data indicate that the level of T cell response 
correlates with the disease severity (22).  
 
3. Cytokine dysregulation 
  During primary DENV infection inflammatory cytokines are secreted from 
infected cells, which is important for attracting NK cells, T and B cells and the 
initiation of adaptive immunity. The level of cytokines released during primary 
infection is not likely detrimental to the host. However, during secondary infection 
cross-reactive T cells from the primary infection are expanded and secrete 
inflammatory cytokines rapidly (18). Studies have demonstrated that pro-
inflammatory cytokines and vasoactive cytokines are elevated in patients with DHF 
(23). Levels of TNF⍺, IL-1β, IFN𝛾, IL-8, IL-6, IL-10 and free VEGF-A were elevated 
in patients with DHF compared to patients with DF (10,18,24–26). The magnitude of 
the cytokine levels correlated with the disease severity (18,23). These cytokines, 
especially TNF⍺, increase endothelial vascular permeability contributing to the plasma 
leakage syndrome (23,27).  
 
4. Complement activation 
Complement activation as a result of immune complexes (virus-antibody) or 
immune activation and cytokine production has been proposed to be involved in the 
pathogenesis of plasma leakage in DHF (28).  A significant reduction in complement 
protein levels with a concurrent increase in complement fragments was reported in 
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patients with DHF. The degree of the complement activation correlated with the 
severity of the disease (29). Certain complement fragments such as C3a and C5a are 
known to enhance vascular permeability contributing to the plasma leakage seen in 
DHF. Antibodies to the DENV non-structural protein 1 (NS1) were demonstrated to 
form immune complexes with DENV NS1 protein in the circulation and also on the 
surface of infected cells leading to complement activation (30). Therefore, rapid 
complement activation during secondary infection is likely to contribute to the severity 
of dengue disease. 
5. Viral virulence 
Differences in virulence in naturally circulating DENV strains and serotypes are 
speculated to contribute to dengue disease (31). Viral genetic differences are reported 
to be associated with differences in virulence between DENV strains (32–34). A study 
done on children with acute DENV infections reported secondary DENV2 caused 
more severe disease than DENV1 or DENV4, suggesting that virus genotype affects 
outcome (35). Enhanced pathogenicity was attributable to increased replication of 
DENV2 compared to DENV1. Another study found that primary infection with 
DENV3 from the south east Asia region (SEA) and secondary infection with DENV2, 
DENV3 and DENV4 also from the SEA region, as well as DENV2 and DENV3 from 
non-SEA region increased the risk of  severe dengue disease (36). To make things 
more complicated, extensive diversity is seen within DENV serotypes resulting in 
various genotypes. For example, among different DENV1 strains isolated from the 
2014 Dengue outbreak in China (DENV1A-E), DENV1B had the highest replication 
efficiency and the highest mortality in suckling mice (37). Therefore, virulence of 
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different DENV strains is directly associated with disease severity. 
6. Other factors 
Genetics of the host may also contribute to disease severity. Genome wide 
association studies found polymorphisms within MICB  (Major histocompatibility 
complex class I polypeptide-related sequence B) and PLCE1 (phospholipase C, 
epsilon 1) significantly associated with DSS (38). Human leucocyte antigen (HLA) is 
one of the genetic factors that impacts the immune responses against DENV. DENV 
infection has been reported to induce the expression of HLA class I and II molecules 
on infected cells. Thus, immune responses generated from peptides presented by HLA 
may be responsible for the immunopathology of DENV infection (39). A study done 
on DENV patients and healthy controls from Malaysia reported that HLA-B*53 is 
associated with disease susceptibility, while HLA-A*03 and HLA-B*10 may confer 
protection (40). 
Furthermore, cross-reactivity of anti-NS1 antibodies with thrombocytes, 
endothelial cells and fibrinogen is believed to contribute to hemorrhage and 
coagulopathy (41). Some chronic diseases such as diabetes mellitus also likely 
increase the risk for severe dengue disease (42). One speculation for this effect is the 
further damage of the impaired vasculature in diabetic patients during dengue. Overall 
severe dengue disease is a result of complex interactions between the virus and the 
host. However, dissecting the role of some host factors such as host immune responses 
is complicated by the lack of an experimental animal model that is able to mimic the 





            DENV is an icosahedral, lipid-enveloped virus. Mature DENV is reported to 
be 500 Å in diameter (43). DENV contains a positive-sense single-stranded RNA 
genome of 10.5kb, which can be directly translated inside a living cell. DENV RNA is 
a dynamic molecule and adapts both linear and circular conformations in an infected 
cell (44). The DENV genome codes for 3 structural proteins and 7 non-structural 




Figure 3. Structural and non-structural proteins encoded by the DENV genome 
(Maririang et al., 2013) 
 
The DENV structure is formed by three structural proteins coded by its 
genome. They are the capsid protein (C), prM (membrane) and the envelope protein 
(E). The DENV genome also encodes for seven nonstructural proteins: NS1, NS2A, 
NS2B, NS3, NS4A, NS4B and NS5.  Capsid (C) is a highly basic protein with ~100 
amino acids. Capsid protein is involved in packaging the viral genome and forming 
the nucleocapsid core (45,46). prM (~165 amino acids) and E (~495 amino acids) are 
glycoproteins each having two transmembrane helices (43). prM is cleaved by host 
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furin during the maturation of virus particles yielding the pr peptide and the M protein 
(47). The E protein contains one or more cellular receptor binding sites (48).  
NS1 protein is involved in virus replication, and also can reside on the host cell 
surface or be released from the cell in a hexameric conformation (49,50). NS1 can be 
used as a diagnostic marker to detect early dengue since it is secreted into the blood 
before the production of DENV-specific antibodies (51).  The concentration of NS1 in 
serum correlates with severity of the disease (30).  NS1 is also known to activate the 
NF-𝛋B pathway downstream of TLR4 (52).  
NS2A is a hydrophobic protein that is cleaved by host proteases at the N 
terminus and by the DENV protease NS3, at the C terminus (53). NS2A is reported to 
be involved in viral replication, virus assembly, immune evasion and disease 
pathogenesis (54). NS2B is also a hydrophobic protein that acts as a cofactor for NS3 
proteolytic activity (55). The N-terminal 180 acids of NS3 contains a serine protease 
domain (56). The C-terminal domain of NS3 is involved in viral RNA replication (57). 
The region spanning from amino acids 180 to 618 of NS3 contains a RNA helicase 
and a NTPase motif (57,58).  
NS4A is cleaved from NS3 at the N terminus and from the 2K fragment at the 
C terminus by NS3. NS4A is essential for viral replication (59). NS4B is a 
hydrophobic transmembrane protein which is important for viral replication (60). 
However, studies on the exact role of NS4B in viral replication and pathogenesis are 
still needed. NS5 is the largest protein encoded by the DENV genome. NS5 has 
methyltransferase and RNA-dependent RNA polymerase functions. NS5 is also 
reported to be translocated to the host cell nucleus where it manipulates the host cell’s 
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splicing machinery (61).  Interestingly, NS5 and other DENV proteins are implicated 
in host innate immune evasion by different strategies, which will be discussed later in 
the Chapter 1. 
 
DENV life cycle 
DENV infects a range of human cells including dendritic cells, macrophages, 
monocytes, B cells, T cells, hepatocytes, epithelial cells and endothelial cells (62–64). 
DENV enters human cells via receptor mediated endocytosis. DC-SIGN, mannose 
receptor, CD14, Fc𝛾 receptor and heparan sulfate are known to act as receptors for 
DENV attachment and entry (65–69). The acidic pH in endosomes triggers fusion of 
viral and endosomal membranes releasing the viral genome into the cytosol (70,71). 
Since the DENV genome is a plus strand RNA, protein translation can initiate 
immediately following the release of the genome. The genome is translated into one 
polypeptide that gets processed into individual viral proteins by host and viral 
proteases. Viral replication and assembly take place in membranous structures 
associated with the ER (72). Immature virus particles contain E, prM, the lipid 
membrane and the nucleocapsid. Since these immature particles are not able to induce 
host cell fusion, they are noninfectious. After assembly, the immature virions exit from 
the ER through the trans-Golgi network (Fig 4). During this process, they undergo 
protease- and pH-dependent maturation rendering the virions mature (73,74). The E 
protein undergoes positional reorganization and prM is cleaved by the cellular 
endoprotease, furin (47). The resulting small membrane-anchored M portion remains 
associated with the virion. The cleavage of prM and the disassociation of the pr 
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peptide are important for fusion with the host cell membranes during subsequent 
virion entry into a new cell (47,70). 
 
 
Figure 4. DENV life cycle. The DENV attaches to receptors on host cells and 
internalizes by receptor mediated endocytosis. In endosomes, due to the acidic pH, 
viral and endosomal membranes fuse, releasing the viral genome into the cytosol. 
Viral RNA translation and replication take place at the membranous structures 
associated with the endoplasmic reticulum.  Assembled viral particles exit the host cell 
via the trans-Golgi apparatus. (Adapted from Gerald G et al., 2017) 
 
DENV evasion of innate immune responses 
During the DENV life cycle, viral RNA and viral proteins (pathogen-
associated molecular patterns/ PAMPs) are released into the host cell cytosol. Pattern 
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recognition receptors in the host cell such as TLR3 (Toll like receptor 3), TLR4 (Toll 
like receptor 4), RIG-I (Retinoic acid-inducible gene 1 like receptor) and MDA-5 
(Melanoma differentiation associated protein 5) recognize these PAMPs and initiate 
signaling cascades that culminate in the production of antiviral effectors such as 
interferons (IFN) and pro-inflammatory cytokines. Once secreted, IFNs will bind to 
IFNRs (IFN receptor) on both infected and uninfected cells and signal for the 
induction of “interferon-stimulated genes” (ISG) via the JAK-STAT (Janus kinase-
Signal transducer and activator of transcription) pathway (75–77). DENV has evolved 
different strategies to inhibit these signaling cascades to evade host immune responses 
(78). 
 Cellular mRNA is post-transcriptionally capped at the 5’ end with a N-7 
methyl guanosine and one or two 2’-O methyl nucleotides (79,80). DENV NS5 also 
catalyzes both N-7 and 2’-O methylations sequentially to mimic cellular mRNA and to 
hide sensing by host Pattern Recognition Receptors/ PRRs (81–83).  
 DENV generate detectable amounts of intracellular dsRNA as an intermediate 
of their replication (84). The localization of DENV dsRNA is important for 
recognition by PRRs. However, DENV RNA is reported to be concealed in DENV-
induced membranous structures up to 72hrs post-infection (85). This may give 
DENV an added advantage to hide from host immune responses. Once these RNA 
species leak into the cytosol they can be recognized by RIG-I/MDA-5 and TLR3 
receptors. RIG-I/MDA-5 signal for IFN production, NF-𝛋B and MAPK activation via 
the mitochondrial associated protein MAVS (Mitochondrial antiviral signaling 
protein). It has been reported that DENV NS4A interacts with MAVS and blocks the 
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association of RIG-I and MAVS, inhibiting IFN production (86). Another study 
found that DENV NS2A and NS4B inhibited RIG-I/MDA-5-mediated IFN 
production by blocking TBK1 activation downstream of MAVS (87). 
 STING (Stimulator of IFN genes) is an adapter molecule in the cGAS-DNA 
(Cyclic GMP-AMP synthase) sensing pathway. Activation of the cGAS/STING 
pathway leads to the production of IFNs via IRF phosphorylation and pro-
inflammatory cytokine production via NF-𝛋B activation (88). STING is also known to 
interact with RIG-I and MAVS to enhance anti-viral responses (89,90). DENV NS2B3 
protease complex is known to interact with and cleave STING, downregulating IFN 
responses (91). DENV protease cofactor NS2B is also known to decrease cGAS levels 
by interacting with it and promoting cGAS for autophagosome-mediated degradation 
(92).  
 DENV NS4B protein inhibits IFN-induced STAT1 phosphorylation and 
nuclear translocation, impairing the transcriptional activation of the ISGF3 (Interferon 
stimulated gene factor 3) complex that is important for the expression of antiviral 
genes (93). Moreover, DENV NS5 is known to interact with STAT2 and promote it 
for proteasomal degradation, impeding ISGF3 activation (94).  
 The mitochondrion has emerged as an important organelle in antiviral 
signaling. DENV has been reported to manipulate mitochondrial dynamics to 
counteract antiviral responses and establish infections. DENV NS2B3 interacted with 
and cleaved mitochondrial proteins MFN1 and MFN2 (95). This cleavage resulted in 
fission of mitochondria and inhibition of MAVS-mediated antiviral responses. In 
contrast, studies done by our group have shown that mitochondrial elongation as a 
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result of decreasing levels of mitochondrial protein DRP1 resulted in increased viral 
replication (96). Consistent with these results another study demonstrated that DENV 
NS4B inhibited DRP1 activation leading to mitochondrial elongation and impairment 
of RIG-I-mediated immune responses (97).  
 DENV was also shown to block NF-𝛋B activation downstream of TNFR and 
TLR3 by unknown mechanisms (98,99). The attenuation of NF-𝛋B activation resulted 
in diminished pro-inflammatory cytokine production. Nevertheless, how this 
inhibition was achieved by DENV was not known. 
 Collectively, these studies demonstrate that DENV proteins and RNA 
antagonize host innate immune responses and further damage infected cells. It’s 
plausible to assume that DENV may defeat host immunity at the first line of defense. 
The inhibition of innate immune mechanisms in the initial phase of infection may 
contribute to disease pathogenesis. However, there are still many unanswered 
questions related to the evasion of innate immune mechanisms by DENV. 
 
Objectives of the dissertation 
 
DENV has evolved efficient strategies to counteract innate immune 
mechanisms. Particularly, individual DENV proteins are shown to target crucial host 
proteins to inhibit signaling pathways. RIPK1 (Receptor interacting protein kinase 1) 
has emerged as a central regulator in cell death and inflammation. Various viruses 
have evolved strategies to inhibit RIPK1-mediated signaling. However, no studies had 
been done to investigate RIPK1-mediated signaling in DENV infection. We observed 
a decrease in RIPK1 levels during DENV infection. Therefore, the overall goal of this 
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dissertation was to understand the effect of RIPK1-mediated signaling in DENV 
infection. In particular, we hypothesized that RIPK1-mediated signaling will be 
inhibited by DENV. The specific aims of this study are as follow: 
Specific aim 1: Determining the mechanism by which DENV infection causes 
decreased levels of RIPK1 
Specific aim 2:  Determining the role of DENV in RIPK1 mediated NF-𝛋B activation 






1.  Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The 
global distribution and burden of dengue. Nature [Internet]. 
2013;496(7446):504–7. Available from: http://dx.doi.org/10.1038/nature12060 
 
2.  Wilder-Smith A, Ooi E-E, Vasudevan SG, Gubler DJ. Update on dengue: 
epidemiology, virus evolution, antiviral drugs, and vaccine  development. Curr 
Infect Dis Rep. 2010 May;12(3):157–64.  
 
3.  Islam R, Salahuddin M, Ayubi MS, Hossain T, Majumder A, Taylor-Robinson 
AW, et al. Dengue epidemiology and pathogenesis: images of the future viewed 
through a mirror  of the past. Virol Sin. 2015 Oct;30(5):326–43. 
 
4.  Jing Q, Wang M. Dengue epidemiology. Glob Heal J. 2019;3(2):37–45. 
  
5.  Solomon T, Mallewa M. Dengue and other emerging flaviviruses. J Infect. 2001 
Feb;42(2):104–15.  
 
6.  SABIN AB. Research on dengue during World War II. Am J Trop Med Hyg. 
1952 Jan;1(1):30–50.  
 
7.  Teixeira MG, Barreto ML. Diagnosis and management of dengue. BMJ. 2009 
Nov;339:b4338.  
 
8.  Guzmán MG, Kourí G. Dengue: an update. Lancet Infect Dis. 2002 
Jan;2(1):33–42.  
 
9.  Kautner I, Robinson MJ, Kuhnle U. Dengue virus infection: epidemiology, 
pathogenesis, clinical presentation,  diagnosis, and prevention. J Pediatr. 1997 
Oct;131(4):516–24. 
 
10.  Kalayanarooj S, Vaughn DW, Nimmannitya S, Green S, Suntayakorn S, 
Kunentrasai N, et al. Early clinical and laboratory indicators of acute dengue 
illness. J Infect Dis. 1997 Aug;176(2):313–21.  
 
11.  Póvoa TF, Alves AMB, Oliveira CAB, Nuovo GJ, Chagas VLA, Paes M V. The 
pathology of severe dengue in multiple organs of human fatal cases:  
histopathology, ultrastructure and virus replication. PLoS One. 
2014;9(4):e83386.  
 
12.  Green S, Rothman A. Immunopathological mechanisms in dengue and dengue 




13.  Kouri GP, Guzmán MG, Bravo JR, Triana C. Dengue haemorrhagic 
fever/dengue shock syndrome: lessons from the Cuban epidemic,  1981. Bull 
World Health Organ. 1989;67(4):375–80.  
 
14.  Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue 
infections in Bangkok. Am J Trop Med Hyg. 1988 Jan;38(1):172–80.  
 
15.  Endy TP, Nisalak A, Chunsuttiwat S, Libraty DH, Green S, Rothman AL, et al. 
Spatial and temporal circulation of dengue virus serotypes: a prospective study 
of  primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol. 
2002 Jul;156(1):52–9.  
 
16.  Gibbons R V, Kalanarooj S, Jarman RG, Nisalak A, Vaughn DW, Endy TP, et al. 
Analysis of repeat hospital admissions for dengue to estimate the frequency of 
third  or fourth dengue infections resulting in admissions and dengue 
hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg. 2007 
Nov;77(5):910–3.  
 
17.  Halstead SB. Neutralization and antibody-dependent enhancement of dengue 
viruses. Adv Virus Res. 2003;60:421–67.  
 
18.  Mathew A, Rothman AL. Understanding the contribution of cellular immunity 
to dengue disease pathogenesis. Immunol Rev. 2008;225(1):300–13.  
 
19.  Borges MB, Marchevsky RS, Carvalho Pereira R, da Silva Mendes Y, Almeida 
Mendes LG, Diniz-Mendes L, et al. Detection of post-vaccination enhanced 
dengue virus infection in macaques: An  improved model for early assessment 
of dengue vaccines. PLoS Pathog. 2019 Apr;15(4):e1007721.  
 
20.  Bhat P, Leggatt G, Waterhouse N, Frazer IH. Interferon-γ derived from 
cytotoxic lymphocytes directly enhances their motility and  cytotoxicity. Cell 
Death Dis. 2017 Jun;8(6):e2836.  
 
21.  Sellahewa KH. Pathogenesis of Dengue Haemorrhagic Fever and Its Impact on 
Case Management. 2013;2013.  
 
22.  Zivna I, Green S, Vaughn DW, Kalayanarooj S, Stephens HAF, 
Chandanayingyong D, et al. T cell responses to an HLA-B*07-restricted epitope 
on the dengue NS3 protein  correlate with disease severity. J Immunol. 2002 
Jun;168(11):5959–65.  
 
23.  Rothman AL. Immunity to dengue virus: A tale of original antigenic sin and 
tropical cytokine storms. Nat Rev Immunol [Internet]. 2011;11(8):532–43. 




24.  Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak 
A, et al. Elevated plasma interleukin-10 levels in acute dengue correlate with 
disease  severity. J Med Virol. 1999 Nov;59(3):329–34.  
 
25.  Hober D, Poli L, Roblin B, Gestas P, Chungue E, Granic G, et al. Serum levels 
of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and  
interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg. 
1993 Mar;48(3):324–31.  
 
26.  Mustafa AS, Elbishbishi EA, Agarwal R, Chaturvedi UC. Elevated levels of 
interleukin-13 and IL-18 in patients with dengue hemorrhagic  fever. FEMS 
Immunol Med Microbiol. 2001 Apr;30(3):229–33.  
 
27.  Anderson R, Wang S, Osiowy C, Issekutz AC. Activation of endothelial cells 
via antibody-enhanced dengue virus infection of  peripheral blood monocytes. J 
Virol. 1997 Jun;71(6):4226–32.  
 
28.  Avirutnan P, Malasit P, Seliger B, Bhakdi S, Husmann M. Dengue virus 
infection of human endothelial cells leads to chemokine production,  
complement activation, and apoptosis. J Immunol. 1998 Dec;161(11):6338–46.  
 
29.  Malasit P. Complement and dengue haemorrhagic fever/shock syndrome. 
Southeast Asian J Trop Med Public Health. 1987 Sep;18(3):316–20.  
 
30.  Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, 
Auethavornanan K, et al. Vascular leakage in severe dengue virus infections: a 
potential role for the  nonstructural viral protein NS1 and complement. J Infect 
Dis. 2006 Apr;193(8):1078–88.  
 
31.  Prommalikit O, Thisyakorn U. DENGUE VIRUS VIRULENCE AND 
DISEASES SEVERITY. Southeast Asian J Trop Med Public Health. 2015;46 
Suppl 1:35–42.  
 
32.  Cologna R, Rico-Hesse R. American genotype structures decrease dengue virus 
output from human monocytes and  dendritic cells. J Virol. 2003 
Apr;77(7):3929–38.  
 
33.  Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I, Chacon  de, et al. 
Dengue virus structural differences that correlate with pathogenesis. J Virol. 
1999 Jun;73(6):4738–47.  
 
34.  Sánchez IJ, Ruiz BH. A single nucleotide change in the E protein gene of 
dengue virus 2 Mexican strain  affects neurovirulence in mice. J Gen Virol. 




35.  Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn 
S, et al. Dengue Viremia Titer , Antibody Response Pattern , and Virus Serotype 
Correlate with Disease Severity. (1):2–9.  
 
36.  Soo K, Khalid B, Ching S, Chee H. Meta-Analysis of Dengue Severity during 
Infection by Different Dengue Virus Serotypes in Primary and Secondary 
Infections. 2016;4–14.  
 
37.  Zou C, Huang C, Zhang J, Wu Q, Ni X, Sun J, et al. Virulence difference of five 
type I dengue viruses and the intrinsic molecular mechanism. PLoS Negl Trop 
Dis. 2019;13(3).  
 
38.  Khor CC, Chau TNB, Pang J, Davila S, Long HT, Ong RTH, et al. Genome-
wide association study identifies susceptibility loci for dengue shock  syndrome 
at MICB and PLCE1. Nat Genet. 2011 Oct;43(11):1139–41.  
 
39.  Wang WH, Urbina AN, Chang MR, Assavalapsakul W, Lu PL, Chen YH, et al. 
Dengue hemorrhagic fever – A systemic literature review of current 
perspectives on pathogenesis, prevention and control. J Microbiol Immunol 
Infect [Internet]. 2020;(xxxx). Available from: 
https://doi.org/10.1016/j.jmii.2020.03.007 
 
40.  Appanna R, Ponnampalavanar S, Lum Chai See L, Sekaran SD. Susceptible and 
protective HLA class 1 alleles against dengue fever and dengue  hemorrhagic 
fever patients in a Malaysian population. PLoS One. 2010 Sep;5(9).  
 
41.  Nasar S. Dengue proteins with their role in pathogenesis , and strategies for 
developing an effective anti ‐ dengue treatment : A review. 2019;(November):1–
15.  
 
42.  Lee I-K, Hsieh C-J, Lee C-T, Liu J-W. Diabetic patients suffering dengue are at 
risk for development of dengue shock  syndrome/severe dengue: Emphasizing 
the impacts of co-existing comorbidity(ies) and glycemic control on dengue 
severity. J Microbiol Immunol Infect. 2020 Feb;53(1):69–78.  
 
43.  Kuhn RJ, Zhang W, Rossmann MG, Pletnev S V, Corver J, Lenches E, et al. 
Structure of dengue virus: implications for flavivirus organization, maturation, 
and  fusion. Cell. 2002 Mar;108(5):717–25.  
 
44.  Villordo SM, Filomatori C V, Sánchez-Vargas I, Blair CD, Gamarnik A V. 
Dengue virus RNA structure specialization facilitates host adaptation. PLoS 
Pathog. 2015 Jan;11(1):e1004604.  
 
45.  Dokland T, Walsh M, Mackenzie JM, Khromykh AA, Ee K-H, Wang S. West 
Nile virus core protein; tetramer structure and ribbon formation. Structure. 2004 
Jul;12(7):1157–63.  
 21 
46.  Ma L, Jones CT, Groesch TD, Kuhn RJ, Post CB. Solution structure of dengue 
virus capsid protein reveals another fold. Proc Natl Acad Sci U S A. 2004 
Mar;101(10):3414–9.  
 
47.  Stadler K, Allison SL, Schalich J, Heinz FX. Proteolytic activation of tick-borne 
encephalitis virus by furin. J Virol. 1997 Nov;71(11):8475–81.  
 
48.  Pokidysheva E, Zhang Y, Battisti AJ, Bator-Kelly CM, Chipman PR, Xiao C, et 
al. Cryo-EM reconstruction of dengue virus in complex with the carbohydrate 
recognition  domain of DC-SIGN. Cell. 2006 Feb;124(3):485–93.  
 
49.  Flamand M, Megret F, Mathieu M, Lepault J, Rey FA, Deubel V. Dengue virus 
type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells  as a 
soluble hexamer in a glycosylation-dependent fashion. J Virol. 1999 
Jul;73(7):6104–10.  
 
50.  Gutsche I, Coulibaly F, Voss JE, Salmon J, d’Alayer J, Ermonval M, et al. 
Secreted dengue virus nonstructural protein NS1 is an atypical barrel-shaped  
high-density lipoprotein. Proc Natl Acad Sci U S A. 2011 May;108(19):8003–8. 
 
51.  Kassim FM, Izati MN, TgRogayah TAR, Apandi YM, Saat Z. Use of dengue 
NS1 antigen for early diagnosis of dengue virus infection. Southeast Asian J 
Trop Med Public Health. 2011 May;42(3):562–9.  
 
52.  Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP, Liu L, et al. 
Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts  
endothelial cell monolayer integrity. Sci Transl Med. 2015 
Sep;7(304):304ra142.  
 
53.  Falgout B, Markoff L. Evidence that flavivirus NS1-NS2A cleavage is mediated 
by a membrane-bound host  protease in the endoplasmic reticulum. J Virol. 
1995 Nov;69(11):7232–43.  
 
54.  Gopala Reddy SB, Chin W-X, Shivananju NS. Dengue virus NS2 and NS4: 
Minor proteins, mammoth roles. Biochem Pharmacol. 2018 Aug;154:54–63.  
 
55.  Falgout B, Pethel M, Zhang YM, Lai CJ. Both nonstructural proteins NS2B and 
NS3 are required for the proteolytic processing  of dengue virus nonstructural 
proteins. J Virol. 1991 May;65(5):2467–75.  
 
56.  Wengler G, Czaya G, Färber PM, Hegemann JH. In vitro synthesis of West Nile 
virus proteins indicates that the amino-terminal  segment of the NS3 protein 
contains the active centre of the protease which cleaves the viral polyprotein 




57.  Xu T, Sampath A, Chao A, Wen D, Nanao M, Chene P, et al. Structure of the 
Dengue virus helicase/nucleoside triphosphatase catalytic domain at  a 
resolution of 2.4 A. J Virol. 2005 Aug;79(16):10278–88.  
 
58.  Luo D, Xu T, Watson RP, Scherer-Becker D, Sampath A, Jahnke W, et al. 
Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein. 
EMBO J. 2008 Dec;27(23):3209–19.  
 
59.  Miller S, Sparacio S, Bartenschlager R. Subcellular localization and membrane 
topology of the Dengue virus type 2  Non-structural protein 4B. J Biol Chem. 
2006 Mar;281(13):8854–63.  
 
60.  Płaszczyca A, Scaturro P, Neufeldt CJ, Cortese M, Cerikan B, Ferla S, et al. A 
novel interaction between dengue virus nonstructural protein 1 and the NS4A-
2K-4B  precursor is required for viral RNA replication but not for formation of 
the membranous replication organelle. PLoS Pathog. 2019 
May;15(5):e1007736.  
 
61.  De Maio FA, Risso G, Iglesias NG, Shah P, Pozzi B, Gebhard LG, et al. The 
Dengue Virus NS5 Protein Intrudes in the Cellular Spliceosome and Modulates  
Splicing. PLoS Pathog. 2016 Aug;12(8):e1005841.  
 
62.  King AD, Nisalak A, Kalayanrooj S, Myint KS, Pattanapanyasat K, 
Nimmannitya S, et al. B cells are the principal circulating mononuclear cells 
infected by dengue virus. Southeast Asian J Trop Med Public Health [Internet]. 
1999 Dec;30(4):718—728. Available from: 
http://europepmc.org/abstract/MED/10928366 
 
63.  Silveira GF, Wowk PF, Cataneo AHD, dos Santos PF, Delgobo M, Stimamiglio 
MA, et al. Human T Lymphocytes Are Permissive for Dengue Virus 
Replication. J Virol. 2018;92(10):e02181-17.  
 
64.  Martina BEE, Koraka P, Osterhaus ADME. Dengue virus pathogenesis: An 
integrated view. Clin Microbiol Rev. 2009;22(4):564–81.  
 
65.  Navarro-Sanchez E, Altmeyer R, Amara A, Schwartz O, Fieschi F, Virelizier J-
L, et al. Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for 
the productive  infection of human dendritic cells by mosquito-cell-derived 
dengue viruses. EMBO Rep. 2003 Jul;4(7):723–8.  
 
66.  Miller JL, de Wet BJM, Martinez-Pomares L, Radcliffe CM, Dwek RA, Rudd 
PM, et al. The mannose receptor mediates dengue virus infection of 
macrophages. PLoS Pathog. 2008 Feb;4(2):e17.  
 
67.  Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, et al. 
Dengue virus infectivity depends on envelope protein binding to target cell 
 23 
heparan  sulfate. Nat Med. 1997 Aug;3(8):866–71.  
 
68.  Chen YC, Wang SY, King CC. Bacterial lipopolysaccharide inhibits dengue 
virus infection of primary human  monocytes/macrophages by blockade of virus 
entry via a CD14-dependent mechanism. J Virol. 1999 Apr;73(4):2650–7.  
 
69.  Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for 
dengue hemorrhagic fever/dengue shock  syndrome: an historical perspective 
and role of antibody-dependent enhancement of infection. Arch Virol. 2013 
Jul;158(7):1445–59.  
 
70.  Harrison SC. Viral membrane fusion. Nat Struct Mol Biol. 2008 Jul;15(7):690–
8.  
 
71.  Stiasny K, Heinz FX. Flavivirus membrane fusion. J Gen Virol. 2006 Oct;87(Pt 
10):2755–66.  
 
72.  Chatel-Chaix L, Bartenschlager R. Dengue virus- and hepatitis C virus-induced 
replication and assembly compartments:  the enemy inside--caught in the web. J 
Virol. 2014 Jun;88(11):5907–11.  
 
73.  Li L, Lok S-M, Yu I-M, Zhang Y, Kuhn RJ, Chen J, et al. The flavivirus 
precursor membrane-envelope protein complex: structure and  maturation. 
Science. 2008 Mar;319(5871):1830–4.  
 
74.  Yu I-M, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, Chipman PR, et al. 
Structure of the immature dengue virus at low pH primes proteolytic 
maturation. Science. 2008 Mar;319(5871):1834–7.  
 
75.  Jensen S, Thomsen AR. Sensing of RNA viruses: a review of innate immune 
receptors involved in recognizing  RNA virus invasion. J Virol. 2012 
Mar;86(6):2900–10.  
 
76.  Doly J, Civas A, Navarro S, Uze G. Type I interferons: expression and 
signalization. Cell Mol Life Sci. 1998 Oct;54(10):1109–21.  
 
77.  Haller O, Kochs G, Weber F. The interferon response circuit: induction and 
suppression by pathogenic viruses. Virology. 2006 Jan;344(1):119–30.  
 
78.  Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev 
Immunol. 2014 Jan;14(1):36–49.  
 
79.  Furuichi Y, LaFiandra A, Shatkin AJ. 5’-Terminal structure and mRNA stability. 




80.  Hyde JL, Diamond MS. Innate immune restriction and antagonism of viral 
RNA lacking 2׳-O methylation. Virology. 2015 May;479–480:66–74.  
 
81.  Hyde JL, Gardner CL, Kimura T, White JP, Liu G, Trobaugh DW, et al. A viral 
RNA structural element alters host recognition of nonself RNA. Science. 2014 
Feb;343(6172):783–7.  
 
82.  Egloff M-P, Decroly E, Malet H, Selisko B, Benarroch D, Ferron F, et al. 
Structural and functional analysis of methylation and 5’-RNA sequence 
requirements  of short capped RNAs by the methyltransferase domain of 
dengue virus NS5. J Mol Biol. 2007 Sep;372(3):723–36.  
 
83.  Liu L, Dong H, Chen H, Zhang J, Ling H, Li Z, et al. Flavivirus RNA cap 
methyltransferase: structure, function, and inhibition. Front Biol (Beijing). 2010 
Aug;5(4):286–303.  
 
84.  Westaway EG, Mackenzie JM, Kenney MT, Jones MK, Khromykh AA. 
Ultrastructure of Kunjin virus-infected cells: colocalization of NS1 and NS3 
with  double-stranded RNA, and of NS2B with NS3, in virus-induced 
membrane structures. J Virol. 1997 Sep;71(9):6650–61.  
 
85.  Uchida L, Espada-Murao LA, Takamatsu Y, Okamoto K, Hayasaka D, Yu F, et 
al. The dengue virus conceals double-stranded RNA in the intracellular 
membrane to  escape from an interferon response. Sci Rep. 2014 Dec;4:7395.  
 
86.  He Z, Zhu X, Wen W, Yuan J, Hu Y, Chen J, et al. Dengue Virus Subverts Host 
Innate Immunity by Targeting Adaptor Protein MAVS. J Virol. 2016 
Aug;90(16):7219–30.  
 
87.  Dalrymple NA, Cimica V, Mackow ER. Dengue Virus NS Proteins Inhibit RIG-
I/MAVS Signaling by Blocking TBK1/IRF3  Phosphorylation: Dengue Virus 
Serotype 1 NS4A Is a Unique Interferon-Regulating Virulence Determinant. 
MBio. 2015 May;6(3):e00553-15.  
 
88.  Abe T, Barber GN. Cytosolic-DNA-mediated, STING-dependent 
proinflammatory gene induction necessitates  canonical NF-κB activation 
through TBK1. J Virol. 2014 May;88(10):5328–41.  
 
89.  Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that 
facilitates innate immune signalling. Nature. 2008 Oct;455(7213):674–8.  
 
90.  Zhong B, Yang Y, Li S, Wang Y-Y, Li Y, Diao F, et al. The adaptor protein 
MITA links virus-sensing receptors to IRF3 transcription factor  activation. 




91.  Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D, et al. DENV 
Inhibits Type I IFN Production in Infected Cells by Cleaving Human STING. 
PLoS Pathog. 2012;8(10).  
 
92.  Aguirre S, Luthra P, Sanchez-Aparicio MT, Maestre AM, Patel J, Lamothe F, et 
al. Dengue virus NS2B protein targets cGAS for degradation and prevents 
mitochondrial DNA sensing during infection. Nat Microbiol [Internet]. 
2017;2(March):1–11. Available from: 
http://dx.doi.org/10.1038/nmicrobiol.2017.37 
 
93.  Muñoz-Jordan JL, Sánchez-Burgos GG, Laurent-Rolle M, García-Sastre A. 
Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A. 
2003 Nov;100(24):14333–8.  
 
94.  Ashour J, Laurent-Rolle M, Shi P-Y, Garcia-Sastre A. NS5 of Dengue Virus 
Mediates STAT2 Binding and Degradation. J Virol. 2009;83(11):5408–18.  
 
95.  Yu CY, Liang JJ, Li JK, Lee YL, Chang BL, Su CI, et al. Dengue Virus Impairs 
Mitochondrial Fusion by Cleaving Mitofusins. PLoS Pathog. 2015;11(12):1–24. 
  
96.  Barbier V, Lang D, Valois S, Rothman AL, Medin CL. Dengue virus induces 
mitochondrial elongation through impairment of Drp1-triggered mitochondrial 
fission. Virology [Internet]. 2017;500(November 2016):149–60. Available 
from: http://dx.doi.org/10.1016/j.virol.2016.10.022 
 
97.  Bender S, Neufeldt CJ. Dengue Virus Perturbs Mitochondrial Morphodynamics 
to Dampen Innate Immune Article Dengue Virus Perturbs Mitochondrial 
Morphodynamics to Dampen Innate Immune Responses. 2016;342–56.  
 
98.  Chang TH, Chen SR, Yu CY, Lin YS, Chen YS, Kubota T, et al. Dengue virus 
serotype 2 blocks extracellular signal-regulated kinase and nuclear factor-κB 
activation to downregulate cytokine production. PLoS One. 2012;7(8):4–11.  
 
99.  Wati S, Rawlinson SM, Ivanov RA, Dorstyn L, Beard MR, Jans DA, et al. 
Tumour necrosis factor alpha (TNF-α) stimulation of cells with established 
dengue virus type 2 infection induces cell death that is accompanied by a 
reduced ability of TNF-α to activate nuclear factor κb and reduced sphingosine 






This manuscript was prepared for submission to mBio 
 
 









1Institute for Immunology and Informatics, Department of Cell and Molecular 



















RIPK1 was first discovered by Stanger et al. as a Fas binding protein important 
for programmed cell death in response to Fas ligation (1). Since then it has emerged as 
a central molecule regulating several biological pathways leading to cell death and 
inflammation. Its role is of particular interest in immune regulation. The primary goal 
of the immune system is to protect the host from invading pathogens. For this purpose, 
the innate immune system in particular has evolved multiple signaling networks that 
culminate in the production of cytokines, chemokines, and interferons. RIPK1 is 
located at the intersection of several signaling pathways and initiates signaling from 
both membrane-bound receptors and intracellular pattern recognition receptors that are 
important in pathogen recognition.  Consequently, pathogens including viruses target 
RIPK1 to evade host immune responses. Thereby these pathogens have managed to 
establish effective infections. Accordingly, there is an unexpected diversity in the 
strategies exploited by viruses to target RIPK1. This review aims to summarize current 
knowledge of RIPK1 signaling in innate immune regulation. Furthermore, we explore 
various mechanisms utilized by viruses to inhibit RIPK1 signaling, with the goal of 
understanding subsequent outcomes that ultimately benefit viruses. 
 
The structure of RIPK1 
  RIPK1 is a member of the receptor-interacting serine/threonine family. RIPK1 
harbors an N-terminal kinase domain, an RHIM (RIP homotypic interaction motif)-
containing intermediate domain (ID), and a C-terminal death domain (DD) (1–
3)(Fig.1). The kinase activity and the ability of RIPK1 to interact with other DD-
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containing and RHIM-containing proteins make it a multifunctional protein involved 
in many cellular pathways (4,5). RIPK1 mediates signaling downstream of TNFR1, 
TLR3, TLR4, RIG-I/MDA-5, and ZBP1. These signaling events culminate in NF-𝛋B-, 
MAPK-, and IRF3/7-mediated cytokine, chemokine, and interferon production, which 
is vital for controlling infections. In the sections below, we discuss in detail major 
signaling events mediated by RIPK1. 
 
Figure 1. Domain structure of RIPK1. RIPK1 consists of an N-terminal kinase 
domain, an intermediate domain and a C-terminal death domain. (Adapted from 
Ofengeim D & Yuan J, 2013) 
 
RIPK1 signaling downstream of TNFR1 
TNFɑ ligation with TNFR1 (TNF Receptor 1) initiates signaling cascades 
leading to NF-𝛋B activation, MAPK activation, extrinsic apoptosis and necroptosis 
(Fig 2).  RIPK1 acts as a critical signal transducer in the NF-𝛋B pathway downstream 
of TNFR1. NF-𝛋B signaling is vital for the regulation of the immune system. NF-𝛋B 
family members (p50, p52, RelA, c-Rel, and RelB) regulate the transcription of pro-
inflammatory cytokines and anti-microbial effectors such as IL-6, IL-8, IL-10, CCL5, 
TNFɑ, CCR5, etc. (7). They also regulate genes involved in cellular proliferation, 
differentiation, and survival (8–11). Thereby, NF-𝛋B transcription factors regulate 
various aspects of both innate and adaptive immune responses. Pathogens have 
evolved mechanisms to downregulate the NF-𝛋B activation in order to evade the host 
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immune and inflammatory responses (12). For example, human rotavirus and DENV  
antagonize the NF-𝛋B pathway leading to downregulated cytokine responses (13,14).  
The role of RIPK1 in TNFɑ signaling is well studied. Upon TNFɑ ligation, 
TRADD (TNFR1 associated death domain protein) binds to the cytoplasmic death 
domain (DD) of TNFR1 (TNF receptor 1).  TRADD recruits TRAF2/ TRAF5 (TNF 
associated factors) along with RIPK1 and cIAP proteins (Cellular inhibitor of 
apoptosis). Ubiquitination of RIPK1 by TRAF2 and/or cIAPs creates a platform for 
recruiting TAK1, TAK binding proteins (TAB1 and TAB2) and the IKK complex 
(NEMO, IKKɑ, IKKß) (15–17).This protein complex downstream of TNFR1 is 
known as complex I (Fig 1). The IKK complex phosphorylates I𝛋B⍺ and promotes it 
for proteasomal-mediated degradation. This liberates NF-𝛋B transcription factors, 
from the inhibitor I𝛋B⍺ and allows them to translocate into the nucleus resulting in 
induction of antiviral genes.  Studies done on mice with a genetic mutation in RIPK1 
destroying its kinase activity, demonstrated intact NF-𝛋B responses following TNFɑ 
stimulation.  Treatment with Necrostatin-1, a specific inhibitor of RIPK1 kinase 
activity did not affect TNFɑ-induced NF-𝛋B responses in mice (18,19). These data 
indicate that the kinase activity of RIPK1 is dispensable for NF-𝛋B activation. 
MAPKs (Mitogen associated protein kinases) consist of three groups, known 
as Erk1/2 (Extracellular signal-regulated kinases), JNKs (Jun N-terminal kinases), and 
p38 (20,21). The MAPK pathway culminates in AP-1 transcription and induces the 
expression of genes important for host defense during pathogen invasion. AP-1 
regulates the expression of pro-inflammatory cytokines and chemokines such as IL-2, 
IFN𝛾,	 TNF⍺, IL-6, IL-4, GM-CSF, CXCL8. Thereby AP-1 regulates leukocyte 
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activation and differentiation (22,23). Therefore, numerous pathogens target the 
MAPK pathway to evade the aforementioned host immune responses. For example, 
DENV did not activate Erk 1/2 phosphorylation and even impaired the basal level of 
p-Erk1/2 in A549 cells (14).   
RIPK1 is placed at a crucial point in MAPK signal transduction downstream 
of TNFR1. RIPK1 ubiquitination in complex I by TRAF2 or cIAPs leads to the 
assembly of a TAK1, TAB2, TAB3 complex. TAK1 phosphorylates MAPKs such as 
p38, JNK, and Erk leading to the expression of additional transcription factors, ATF2, 
JUN, and TCF, which translocate into the nucleus facilitating AP-1 transcription (24). 
The ID of RIPK1 is necessary and sufficient for the activation of MAPKs upon TNF⍺ 
stimulation (25). Conversely, another study demonstrated that RIPK1 mediated TNF⍺-
induced p38 MAPK activation by recruiting MEKK3 (Mitogen-activated protein 
kinase kinase kinase 3) to TNFR1 (26). The authors showed that RIPK1 transiently 
interacted with MEKK3 upon TNF⍺ stimulation. Even though this interaction 
occurred via the RIPK1 ID, the kinase activity of RIPK1 was important for a stable 
interaction. A RIPK1- MEKK3 interaction was observed in cells expressing wild type 
RIPK1 but not in cells expressing kinase-inactive RIPK1.These reports suggest that 
there may be more than 1 routes of MAPK activation in complex I via RIPK1. 
Targeted disruption of the rip1 gene (which codes for RIPK1) in Mouse embryonic 
fibroblasts prevented p38 MAPK activation and IL-6 production in response to TNF⍺ 
(26).  exhibiting the vital role of RIPK1 in regulating MAPK-AP-1 signaling 




RIPK1 signaling downstream of TLR3 and TLR4 
Stimulation of toll like receptors (TLRs) can lead to potent innate immune 
responses via NF-𝛋B activation. TLR4, the immune sensor for bacterial LPS, triggers 
NF-𝛋B activation via either MyD88 (Myeloid differentiation primary response gene 
88)-dependent or TRIF (TIR domain-containing adapter inducing interferon β )-
dependent signaling pathways (27,28). TLR3 participates in recognition of pathogen-
associated double-stranded (ds) RNA and the synthetic analog of viral ds RNA, poly 
(I:C). Unlike TLR4, TLR3 induces NF-𝛋B activation only via TRIF (29).  In both 
TLR3 and TLR4 signaling, TRIF interacts with RIPK1 via  a conserved four amino 
acid motif (VQLG) in the C-terminal RHIM domain of TRIF (30). TRIF also recruits 
TRAF6 and TBK1 via its N terminus (29). These interactions result in IKK activation 
and I𝛋B phosphorylation, liberating NF-𝛋B, which translocates to the nucleus and 
initiates transcription of genes involved in immune responses (31).  TRIF-RIPK1 
interaction results in recruitment of TAK1 leading to the activation of MAPKs and 
AP-1 activation leading to enhanced immune responses (32). Even though this 
tethering of signaling molecules by RIPK1 (scaffolding function) is sufficient for NF-
𝛋B and MAPK activation, a RIPK1 kinase activity-dependent mechanism was 
recently reported (33). The kinase activities of RIPK1 and RIPK3 promoted sustained 
activation of Erk, cFos and NF-𝛋B in LPS-stimulated macrophages. Regulation was 
induced in the absence of caspase 8 activity and was dependent on TRIF. Even though 
the speculation is that this signaling initiated from a death signaling complex 
involving RIPK1, (necrosome), the detailed molecular mechanism remains to be 
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elucidated. It is tempting to conjecture that similar RIPK kinase activity-dependent 
signaling could occur downstream of TLR3 as well.  
RIPK3 has been shown to inhibit RIPK1-mediated NF-𝛋B activation by 
competitive binding to TRIF downstream of TLR3 and TLR4 (29). The RIPK3-TRIF 
interaction could potentially inhibit RIPK1-driven MAPK activation, even though this 
has not been investigated so far. Therefore, it could be of interest to study the effect of 
RIPK3 on TLR3/TLR4-stimulated MAPK pathway.  
TLR3 and TLR4 activate signaling pathways that culminate in the production 
of IFNs and IFN-inducible genes through IRF3/IRF7 phosphorylation, which is 
central to antiviral innate immune responses (34). Even though RIPK1 interacts with 
TRIF, involvement of RIPK1 in TRIF-dependent IRF3/IRF7 signaling is somewhat 
less clear. Overexpression of the RHIM domain of RIPK1 alone was sufficient to 
induce TRIF-mediated NF-𝛋B activation as measured using a luciferase reporter. 
However, the activity of an IFNβ luciferase reporter was not induced with 
overexpression of either a WT or RHIM mutant RIPK1 (29).  ISRE reporter luciferase 
activity increased in HEK293 cells with overexpression of TRIF but not with  
overexpression of RIPK1 (35). This RIPK1-independent response in IRF3/7 
phosphorylation could be due to the ability of TRIF to directly interact with both IRF3 
and the IRF3-activating kinase, TBK1 (31) However, RIPK1-dependent regulation of 
IRF3/7 activation was shown by studies done by Hyun et al. (36). The authors 
suggested that the Human T lymphotropic virus (HTLV-1) Tax protein prevented 
TLR3-induced IRF3 phosphorylation by competitively binding to TRIF (36).  
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Therefore, more mechanistic studies would be needed to resolve discrepancies 
regarding RIPK1 regulation of IRF3/7 activation downstream of TLR3 and TLR4. 
 
RIPK1 signaling downstream of RIG-I and MDA-5 
The RNA helicases RIG-I (Retinoic acid-inducible gene 1) and MDA-5 
(Melanoma differentiation-associated protein 5) are known to initiate signaling 
pathways culminating in the production of type I interferons (IFN⍺, IFNβ, IFNε, 
IFN𝛋)  and pro-inflammatory cytokines during the early stages of viral infections (37). 
It has been reported that RIG-I most strongly recognizes short 5’ppp dsRNA, while 
MDA5 recognizes preferentially long dsRNA (38,39). RIG-I most potently detects 
influenza viruses, filoviruses, and rhabdoviruses while MDA5 is essential for the 
recognition of picornaviruses, arteriviruses, and hepatitis D virus (40–44). These 
receptors are also involved in recognizing non-viral pathogens; MDA5 has been 
reported to respond to Malaria parasites (45). Nevertheless, viruses have evolved 
strategies to impair signaling downstream of RIG-I/MDA-5. For example, the DENV 
protease NS3 was shown to cleave mitochondrial associated proteins MFN1 and 
MFN2 impairing efficient RLR signaling (46). Influenza A H1N1 viral protein NS1 
directly interacts with RIG-I and prevents its activation, inhibiting IFNβ production 
(47). 
RIPK1 is involved in NF-𝛋B, MAPK, IRF3 and IRF7 activation downstream 
of RIG-I and MDA5. RIG-I and MDA5 signaling merge at the mitochondria through 
MAVS (Mitochondrial antiviral signaling protein), which is located at the 
mitochondrial membrane (48). TRADD and FADD are required to recruit RIPK1 to 
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MAVS following RIG-I/MDA-5 stimulation (49).  RIPK1 signaling to NF-𝛋B 
proceeds through the IKK complex, while signaling to IRF3/IRF7 proceeds through 
TBK1 and IKKɛ (50,51).  Activation of MAPK downstream of RIG-I involves 
TRAF2, TAK1, and the kinase activity of RIPK1 (52). RIG-I and MDA-5 activate 
NF-𝛋B and p38 MAPK through a common upstream pathway involving RIPK1 and 
only diverge downstream of TAK1. Therefore, RIPK1 functions as an essential 
adaptor molecule in RIG-I and MDA-5 signal transduction by facilitating the 
association of other proteins (51). 
 
RIPK1 signaling in cell death - Ripoptocide 
Viruses are obligate intracellular pathogens that require living cells. Hence, 
cell death can be an important immune defense against infection. RIPK1 regulates cell 
death pathways known as “ripoptocide” involving both apoptosis and necroptosis (53). 
Apoptosis is a non-inflammatory form of cell death having morphological changes 
such as cell shrinkage, chromatin condensation, and plasma membrane blebbing (54). 
Apoptosis can be induced by extrinsic or intrinsic stimuli. Extrinsic apoptosis is 
mediated by death receptors such as TNFR1 whereas intrinsic apoptosis is driven by 
intrinsic stresses such as DNA damage, growth factor withdrawal, or ER stress leading 
to mitochondrial outer membrane permeabilization (54,55). RIPK1 is involved in 
regulating extrinsic apoptosis downstream of TNFR1. Deubiquitination of RIPK1 
leads to the formation of a complex with Pro-Caspase 8 and FADD in response to 
TNF⍺ stimulation, which is referred to as complex IIa (Fig 2) (6). Assembly of 
complex IIa leads to auto-processing and maturation of pro-caspase 8 into caspase 8, 
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which initiates extrinsic apoptosis. A similar complex known as the ripoptosome 
assembles in response to TLR3 and TLR4 stimulation (56,57). The core of the 
ripoptosome consists of RIPK1, FADD, and Caspase 8 (57). The ripoptosome can also 
recruit additional proteins such as cFLIP (FLICE like inhibitory protein) and RIPK3 
depending on the cell type and stimulus (57).  As in complex IIa, the ripoptosome 
promotes caspase 8 activation. Mature caspase 8, in turn, activates downstream 
caspases such as caspase 3 resulting in extrinsic apoptosis. Active caspase 8 also 
cleaves RIPK1 downstream of residue Asp 324 in the ID during apoptosis. The C-
terminal 38kDa cleavage product generated from this cleavage is known to facilitate 
interactions between FADD and TRADD, further contributing to extrinsic apoptosis. 
The expression of RIPK1 mutants resistant to caspase 8 cleavage protected cells 
against TNF⍺-induced apoptosis demonstrating the pro-apoptotic nature of cleaved 
RIPK1 (58). The induction of apoptosis by RIPK1 contributes to virus clearance by 
eliminating infected cells, however, it’s an immunologically silent form of cell death 
because it does not cause inflammation.  
Necroptosis is considered as an anti-viral defense mechanism because it can 
initiate a strong pro-inflammatory response. Necroptosis is morphologically 
characterized by swelling of organelles followed by plasma membrane rupture 
(59)(60,61). Necroptosis protects the host both by limiting pathogen replication in 
infected cells and by promoting inflammatory responses that stimulate host 
adaptive immunity (62).  Necroptotic cell death is driven by a protein complex known 
as the "necrosome". The necrosome includes RIPK1 and RIPK3, which interact with 
and phosphorylate each other. Activated/phosphorylated RIPK3 recruits and 
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phosphorylates MLKL (Mixed lineage domain-like protein). Phosphorylated MLKL 
forms tetramers, translocates to the cell membrane and further polymerizes to form 
amyloid-like structures (63). These polymerization events result in cell membrane 
permeabilization and cell lysis (64). How MLKL polymers disrupt membrane integrity 
is unclear. Necrosomes are formed downstream of TNFR1, TLR3, and TLR4 in the 
absence of caspase 8 activity. Even though RIPK1 participates in extrinsic apoptosis 
and necroptosis, the loss of RIPK1 also sensitizes cells to TNF⍺-induced apoptosis 
(65,66) perhaps due to NF-𝛋B inhibition.  Therefore, a goal of future studies should be 
to understand what factors regulate the final effects of RIPK1 leading to cell survival 
or cell death. Additionally, whether RIPK1 signal for cell death downstream of RIG-I/ 






Figure 2. Signaling pathways mediated by RIPK1. TNFR1 stimulation leads to the 
assembly of complex I, which signals for the NF-kB and MAPK activation. When 
RIPK1 is deubiquitinated in the complex I, signaling is diverted into caspase 8 
maturation and extrinsic apoptosis in complex IIa. In the absence of caspase 8 activity, 
RIPK1 signaling results in induction of necroptosis. TLR4 and TLR3 stimulation 
results in RIPK1-regulated NF-kB and MAPK activation. Extrinsic apoptosis could 
take place in the ripoptosome downstream of TLR3 and TLR4. When caspase 8 
activity is depleted, RIPK1 signals for necroptosis downstream of TLR3 and TLR4. 
RIG-I/MDA-5 signals for IFN induction, NF-kB and MAPK activation via RIPK1. 
 
Viral strategies in modulating RIPK1 signaling 
 RIPK1 is placed at a crucial point in controlling cell death and inflammation. 
RIPK1-mediated signaling governs the outcome of signaling pathways initiated by 
TNFR1, TLR3, TLR4 and RIG-I/MDA-5 by signaling for NF-kB activation, and 
MAPK and IRF3/7 phosphorylation. In the event of an infection, activation of these 
pathways results in release of pro-inflammatory cytokines, chemokines and interferons 
setting an antiviral state. RIPK1 is also involved in destroying replication niches of 
pathogens by signaling for extrinsic apoptosis or necroptosis. Therefore, RIPK1 has 
emerged as an attractive target for inhibition by viruses. Here we have summarized 






Members of the Herpesviridae family have double stranded DNA genomes. 
They are categorized into ⍺, β, and γ herpesviruses based on their host range, genome 
and replication strategies (67). Most vertebrates get infected with one or more 
herpesviruses during their lifetime. Herpesviruses commonly establish a life-long 
infection in the host. Human herpes simplex virus-1 (HSV-1) , an ⍺ herpesvirus, is 
associated with genital herpes, herpes encephalitis and ocular HSV causing blindness 
(68). Human cytomegalovirus (CMV) is a β herpesvirus that causes a wide spectrum 
of pathological outcomes. Congenital CMV infections are often associated with 
serious complications including microcephaly and mental retardation. 
Immunocompromised patients can develop encephalitis, pneumonitis and graft 
rejection as a result of CMV infections (69). Epstein-Barr virus (EBV) is a human γ-
herpesvirus. It’s the primary cause of infectious mononucleosis. EBV infections are 
also associated with ~200,000 malignancies (Burkitt’s lymphoma, non-Hodgkin’s 
lymphoma, nasopharyngeal carcinoma, gastric adenocarcinoma) worldwide every 
year (70). Several members of the herpesvirus family have been shown to impair 
RIPK1-mediated signaling.  
 
1.1 Herpes simplex virus-1 (HSV-1) 
Murine HSV-1 induces necroptosis, which restricts viral propagation (71). In 
contrast, human HSV-1 has evolved to escape necroptosis-mediated restriction by at 
least three mechanisms. In one mechanism, the human HSV-1 protein ICP6 
promotes RIPK1 aggregation and then its degradation by the autophagosome, a 
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process known as aggrephagy (72). A conserved motif in all the human 
herpesviruses known as the “induced protein aggregation motif (IPAM)” is needed 
for this aggregate formation. Expression of wild-type ICP6 alone was sufficient to 
induce aggregate formation in human fibroblasts while expression of a mutant IPAM 
(DIPAM) ICP6 failed to do so (73). However, no experiments were shown to 
indicate if IPAM of ICP6 was important for RIPK1 interaction. In a second 
mechanism it was shown that HSV-1 proteins ICP6 and ICP10 both harbor RHIM 
domains and disrupt the RIPK1-RIPK3 association by competing for RIPK1 binding 
(74). This effect allows HSV-1 to prevent necrosome formation. Recently an 
additional mechanism of necroptosis inhibition by HSV-1 ICP6 via the RHIM 
domain was discovered. Wild type HSV-1 inhibited translocation of necrosomes to 
detergent-resistant membranes as compared with HSV-1 lacking ICP6 (DICP6) or 
having and ICP6 lacking the RHIM domain (ICP6-DRHIM) (75).  Collectively, 
these data show numerous strategies exploited by HSV-1 to prolong cell survival by 
targeting RIPK1. Furthermore, these studies may shed light on similar mechanisms 
shared by other viruses.  
 
1.2 Cytomegalovirus (CMV) 
  The infection of mice with Murine cytomegalovirus (MCMV) is a well-
established model for understanding human CMV infections (76). MCMV M45, the 
homolog of HCMV UL45, has emerged as a viral inhibitor of RIPK1-mediated 
signaling. Mutational studies done on M45 have revealed a RHIM-like domain in 
the N-terminus of MCMV M45 (aa 61-69). Overexpressed WT (wild type) but not 
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∆RHIM M45 co-immunoprecipitated with RIPK1 indicating that M45 interacts with 
RIPK1 via its RHIM domain (77). This strong interaction between RIPK1 and M45  
resulted in blocking of RIPK1 ubiquitination as shown by in vitro ubiquitination 
assays (19). TNF⍺-induced NF-𝛋B activation and TNF⍺-induced p38 
phosphorylation were inhibited as a result of the RIPK1-M45 interaction (78). NF-
𝛋B activation downstream of TLR3 was also blocked by M45. Furthermore, M45 
blocked caspase-independent cell death following TNF⍺ stimulation in a RHIM-
dependent manner. Similarly, MCMV expressing WT M45 but not ∆RHIM M45 
blocked TRIF-induced apoptosis by blocking the RIPK1-TRIF interaction (77). 
Interestingly, another study found an additional mechanism of RIPK1 degradation 
by M45. Muscolino et al. showed that M45 physically interacted with RIPK1 via its 
IPAM motif and caused RIPK1 to aggregate (73). This interaction caused RIPK1 to 
accumulate in the insoluble fraction of cell lysates following MCMV infection in an 
M45-dependent manner. RIPK1 levels were higher in autophagy-deficient ATG5-/- 
cells following MCMV infection, indicating that RIPK1 was subjected to 
degradation by autophagy. Further studies revealed that M45 promoted RIPK1 
degradation which was blocked by inhibition of lysosome function by NH4Cl (73). 
In agreement with previous studies, the authors also detected inhibition of 
necroptosis due to low levels of RIPK1. Both IPAM and RHIM sequences were 
needed for cell survival suggesting that these two sequences have independent roles. 
Infections with MCMV expressing ∆IPAM or ∆RHIM M45 resulted in less viral 
replication in mice relative to infections with WT MCMV. Therefore, M45 
promoted viral replication in cell culture and facilitated viral replication in mice by 
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inhibiting RIPK1-mediated cell death. RIPK3 also harbors a RHIM domain and 
drives signaling for necroptosis. Thus, M45 RHIM-mediated interactions could 
negatively affect RIPK3 signaling as well. Further efforts should be made to 
understand if M45 can regulate RIPK3 signaling. Moreover, how RIPK1 
overexpression affects viral replication could be explored.  
 
1.3 Epstein-Barr virus (EBV) 
EBV is known to manipulate the host cell’s death signaling pathways to 
facilitate viral replication. EBV suppressed necroptosis by targeting RIPK1 (79). 
Latent membrane protein 1 (LMP1) of EBV directly interacted with RIPK1 in an 
RHIM-independent manner. Furthermore, both K48 and K63 ubiquitination of 
RIPK1 increased in the presence of LMP1 as shown by in vitro ubiquitination 
assays. K48 ubiquitination resulted in a decrease of the RIPK1 half-life. LMP1 
increased the expression of TRAF2, which amplified RIPK1 K63 ubiquitination. 
Therefore, LMP1 inhibited TNFR1-stimulated necroptosis by redirecting RIPK1 
signaling towards NF-𝛋B activation by promoting K-63 ubiquitination.  However, 
LMP1 is also known to upregulate TNFAIP3/A20 (TNFa-induced protein 3), which 
could deubiquitinate RIPK1 (80,81). Therefore, studies on the direct effect of low 
levels of RIPK1 and LMP1-RIPK1 interaction on EBV replication and cell death 






 Flaviviruses are single-stranded positive-sense RNA viruses, having a 
genome size of ~11kb. Flaviviruses are mainly transmitted to vertebrate hosts by 
infected mosquitos or ticks. Mosquito-borne flaviviruses include Yellow fever virus, 
Dengue virus, Japanese encephalitis virus, West Nile virus and Zika virus. Tick-borne 
viruses include Tick-borne encephalitis virus, Powassan virus, Louping ill virus, and 
Omsk hemorrhagic fever virus (82). Ongoing research on understanding human-
flavivirus interactions has exposed a protective role of RIPK1 for the host. Some 
flaviviruses have evolved strategies to target RIPK1 in order to evade host responses 
while these mechanisms remain to be elucidated for other flaviviruses.  WNV is an 
encephalitic virus of global concern (83). In humans, ~20% of WNV infections cause 
rashes, arthralgia and myalgia while <1% of infections cause cognitive and 
neurological impairments that can lead to death (84). ZIKV is an emerging flavivirus 




2.1. West Nile virus (WNV) 
RIPK1 together with RIPK3 signals for chemokine expression and for 
recruitment of infiltrating antiviral leukocytes in the central nervous system during 
WNV infection. Mice expressing a kinase dead form of RIPK1 exhibited increased 
susceptibility to WNV infection (87). Even though the molecular mechanisms for this 
effect are not completely understood,  these data suggest a protective role of RIPK1 
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against WNV (87). Additionally, the levels of RIPK1 upon WNV infection could be 
monitored to learn if WNV impede RIPK1 mediated signaling. 
 
2.2 Zika virus (ZIKV) 
The fate of RIPK1 in ZIKV-infected cells has not been directly addressed. 
However, a protective role of RIPK1 against ZIKV was recently reported. RIPK1 
together with RIPK3 diminished ZIKV infection by activating antiviral gene 
networks including IRF1-dependent Irg1 expression (88). The full nature of this 
mechanism remains to be elucidated. However, RIPK1 kinase activity-deficient mice 
(RIPK1KD/KD) had higher viral titers in whole brain homogenates upon infection with 
ZIKV. Inhibition of kinase activity in vivo by treatment with pharmacological 
inhibitors also increased brain viral burden. Furthermore, RIPK1KD/KD neuronal 
cultures exhibited enhanced replication of ZIKV relative to wild-type controls. 
Interestingly, no differences were observed in ZIKV replication in primary BMDM 
or dendritic cells from wild-type versus RIPK1KD/KD mice or with inhibition of the 




 Retroviruses are enveloped RNA viruses (89). Retroviruses are able to reverse 
transcribe their RNA genomes into DNA that integrates into the host cell genome 
during the intracellular virus life cycle. It is estimated approximately 8% of the human 
genome consists of endogenous retroviruses (90). Retroviruses are further categorized 
into oncoretroviruses, lentiviruses and spumaviruses (91). Human Immunodeficiency 
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Virus 1 (HIV-1) is a lentivirus while Human T-Cell Lymphotropic Virus-1 (HTLV-1) is 
an oncoretrovirus. HIV-1 causes acquired immunodeficiency syndrome (AIDS). 
Approximately 37 million people were living with HIV-1 worldwide as of 2017 (92). 
Infection of T-lymphocytes by HTLV-1 can cause adult T-cell leukemia (ATL) or 
HTLV-1 associated myelopathy (HAM) (93,94). Both HIV-1 and HTLV-1 have been 
shown to modulate RIPK1 signaling. 
 
3.1 Human Immunodeficiency Virus 1(HIV-1) 
The HIV-1 protease (PR) plays an important role in the virus life cycle by 
cleaving viral poly-peptides Gag and Gag-Pol into mature proteins (95). One study 
examined the effect of HIV-PR expression on RIPK1-mediated signaling (96) HIV-1 
PR was shown to decrease both endogenous and overexpressed RIPK1. A catalytically 
inactive PR and the PR inhibitor Saquinavir (SQV) prevented this cleavage. Mass 
spectroscopy studies revealed that PR cleaves RIPK1 at the ID domain. RIPK1 
cleavage was confirmed in HIV-1-infected T cell lines and primary CD4+ T cells. PR 
cleavage of RIPK1 disrupted NF-𝛋B activation as measured by luciferase reporter 
assays, and this activation was restored by the addition of SQV. Furthermore, PR 
overexpression impaired RIPK1-RIPK3 interaction as demonstrated by a yeast two-
hybrid system. These data suggest that RIPK1 cleavage by PR can block necrosome 
formation inhibiting necroptosis. However, this study did not assess the effect of PR 
on RIPK1-mediated MAPK pathway activation. Collectively these data indicate that 
HIV-1 PR can block multiple immune pathways by cleaving RIPK1. However, the 
effect of RIPK1 cleavage on HIV-1 replication remains to be studied. 
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3.2 Human T-Cell Lymphotropic Virus -1 
The HTLV-1-encoded Tax protein is a multifunctional protein that is crucial 
for T cell transformation by HTLV-1 (97).  Moreover, Tax inhibits innate immune 
signaling by multiple mechanisms via RIPK1. Type I IFNs and ISGs are capable of 
inhibiting HTLV-1 replication. Therefore, viral evasion of IFN production and 
signaling probably represents a survival strategy. More progeny viruses were 
recovered following VSV infection in primary MEF and Jurkat cells overexpressing 
Tax protein relative to controls, demonstrating inhibition of host immune responses by 
Tax (36). HTLV-1-infected cells produced less IFNβ than uninfected cells upon 
stimulation with poly(I:C). Yeast two hybrid screens and mutational constructs 
revealed a Tax interaction with RIPK1 via the RHIM in the ID domain of RIPK1(36). 
However, they did not test for the presence of a RHIM domain in Tax protein. The 
Tax-RIPK1 interaction prevented the RIPK1-IRF7 interaction and inhibited IRF7 
phosphorylation, downregulating the production of IFN⍺ and IFNβ. In contrast, Tax 
did not prevent RIPK1-RIG-I/MDA-5 interactions, and NF-𝛋B signaling was 
unaffected as shown by luciferase assays (36). HTLV-1 is known to induce persistent 
activation of NF-𝛋B, which contributes to the T-cell transformation (98). It was shown 
that Tax prevented TLR3-induced IRF3 phosphorylation but not NF-𝛋B signaling by 
competitively binding to TRIF. However, this observation is inconsistent, since TRIF 
is located upstream of both IRF3 and NF-𝛋B pathways. Therefore, it is reasonable to 




4. Other viruses 
 
4.1 Human Rhinovirus (HRV) 
HRV is the major causative agent of the common cold and asthma 
exacerbations (99). There are approximately 170 serologically distinct HRV types in 
circulation (100). HRV is a single-stranded positive-sense RNA virus.  The HRV 
genome encodes for three proteases (2A, 3CD, 3C), which are important for viral 
polyprotein maturation (101). These proteases have also been shown to cleave host 
proteins. The HRV16 3C protease restricted host cell apoptosis and prolonged cell 
survival by cleaving RIPK1 in HeLa cells (102). The addition of a 3C protease 
inhibitor, Rupintrivir, decreased RIPK1 cleavage. 3C-mediated RIPK1 cleavage was 
increased upon caspase 8 activation by ActoD relative to untreated cells. However, 
this observation of increased RIPK1 cleavage with activation of Caspase 8 was not 
reproduced in HRV16-infected cells. Even though apoptosis induced with ActoD 
treatment decreased upon HRV16 infection, no evidence was shown this was related 
to RIPK1 cleavage. Additional studies may require for elucidating the direct effect of 
RIPK1 cleavage on cell death as well as HRV16 replication. Finally, given that the 
level of full-length RIPK1 is decreased during HRV16 infection, it would be 
interesting to learn if RIPK1-mediated innate immune signaling such as NF-𝛋B and 
MAPK pathways are disrupted. Therefore, there is an opening to investigate the 
inhibition of RIPK1-mediated immune responses by HRV. 
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4.2 Ebola virus (EBOV) 
EBOV is a negative-strand RNA virus belonging to the Filoviridae family 
(103). Ebola virus causes Ebola Virus Disease, a hemorrhagic fever with a high 
fatality rate. Damaging host immune responses due to robust EBOV replication 
contributes to the disease severity. This excessive viral replication reflects the 
capability of EBOV to suppress innate immune mechanisms. For example, EBOV 
effectively blocks IFN production (104,105). EBOV has been shown to disrupt 
RIPK1-mediated signaling by encoding a miRNA (miR-T2-3p) targeting RIPK1 
(106). In vitro experimental studies in HeLa cells demonstrated that a mimic of 
miRNA miR-T2-3p downregulated RIPK1 transcript levels. In light of this 
observation, it is tempting to hypothesize that EBOV-encoded miRNA blocks RIPK1-
mediated innate immune responses to enhance viral replication. Perhaps RIPK1 
inhibition could be responsible for inhibition of IFN production by EBOV. Thus, it 
will be of interest to study the link between RIPK1 downregulation and IFN inhibition 
during EBOV infection. Also, the effect of RIPK1 inhibition on EBOV replication 
could be further explored.  
 
4.3 Vaccinia virus (VACV) 
VACV belongs to the poxvirus family. It has a large linear ds DNA genome. 
VACV is the primary component of the smallpox vaccine. VACV is mostly used as a 
tool in the research setting for vaccine development (107). RIPK1 has been shown to 
play a protective role in VACV infection by inducing necroptosis. Caspase 8 
inhibition by VACV also promotes necroptosis in infected cells (108). Mice 
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expressing a kinase inactive RIPK1 mutant failed to control VACV replication in vivo. 
They had increased viral titers in the spleen and the liver, due to lack of necroptosis 
(109). This study provides genetic evidence that the kinase activity of RIPK1 is 
essential for viral-initiated necroptosis. However, further efforts should be made to 





                 
Figure 3. Viral proteins involved in modulating RIPK1 signaling. HIV-1 PR, 
CMV M45 proteins block NF-kB activation. CMV M45 blocks MAPK activation and 
downstream signaling. HTLV-1 Tax protein blocks IRF3/IRF7 by binding to RIPK1. 
HSV-1 ICP6, HIV-1 PR, CMV M45, EBV LMP1 all are shown to block necroptosis 





 As discussed in this review, RIPK1 plays a crucial role in cell death and 
inflammatory responses. RIPK1 is placed at an intersection of multiple pathways of 
signal transduction initiated from death receptors and pattern recognition receptors. 
Signaling initiated from these receptors is important for the induction of immune 
responses. Importantly, new properties of RIPK1 signaling are emerging. For example, 
it was previously reported that RIPK1 was not involved in TRIF-mediated IRF3/IRF7 
signaling. In contrast, Hyun. J. et al., suggest a role of RIPK1 phosphorylating IRF3 
downstream of TLR3 and TRIF (36). Additionally, it has been long postulated that the 
kinase activity of RIPK1 is dispensable for NF-𝛋B activation (110). Nevertheless, a 
RIPK1 kinase activity-dependent mechanism of NF-𝛋B activation and induction of 
inflammatory responses due to TLR4 stimulation was recently reported (33). RIPK1 is 
involved in driving signaling for extrinsic apoptosis in response to TNFa stimulation. 
However, RIPK1 was also reported to be implicated in protecting TNFa stimulated 
cell death in hepatocytes suggesting opposing roles of RIPK1 in the same pathway 
(114). Furthermore, RIPK1 was shown to induce antiviral gene networks by undefined 
mechanisms (88).  
 Evidence demonstrating that RIPK1 is involved in suppressing cell death and 
inflammation while also promoting the same supports RIPK1 as a critical regulator in 
cell death and inflammation signaling network. Under normal conditions, RIPK1 
regulation of cell death and inflammation seem to be tightly regulated to allow 
homeostasis. However, in the setting of viral infection, this homeostasis appears to be 
disturbed. In most viral infections, RIPK1-mediated signaling protects the host by 
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either inducing cell death or inflammatory cytokine, IFN secretion.  For example, 
RIPK1 kinase activity-deficient mice had higher viral titers than wild-type mice 
following ZIKV and VACV infections, and these mice showed increased susceptibility 
to WNV infection (88,109,111). If the overall effect of RIPK1 is to inhibit infection, 
RIPK1 becomes an attractive target for inhibition by viruses, especially due to the fact 
that many signaling pathways can be blocked simultaneously. It is surprising yet 
fascinating to observe the wide spectrum of mechanisms utilized by viruses to inhibit 
RIPK1. As shown in Fig 3, numerous viral proteins are implicated in RIPK1-mediated 
signaling. Additionally, understanding viral strategies used for evasion of RIPK1 
signaling has revealed the multifunctionality of viral proteins. This is exemplified by 
the identification of distinct motifs such as RHIM and IPAM domains in viral proteins. 
For example, the IPAM motif is present in more than 70 viral R1 homologs of 
herpesviruses and baculoviruses suggesting that its function of inducing protein 
aggregation might be widely conserved (73). Understanding viral strategies of RIPK1 
inhibition could potentially point towards unexplored viral-host interactions. Seeing 
such a variety of strategies evolved in viruses indicates the possibility that RIPK1 
inhibition is more important for viral survival than has been known.  
 Since RIPK1 controls the outcome of many signaling pathways, the sum of the 
diverse functions attributable to RIPK1 may cooperatively contribute to the outcome. 
Therefore, it may be helpful to investigate the outcome of all the possible arms of 
innate immune responses controlled by RIPK1 during pathogen invasions. In 
particular, how the outcome of RIPK1 signaling affects viral replication could be 
studied. Physiologic extracellular signals that initiate RIPK1-mediated signaling could 
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differ between in vivo and in vitro experimental models. For example, extracellular 
pH, oxidants, and Ca2+ are known to trigger necroptosis (112). Therefore, distinct 
outcomes due to RIPK1 inhibition between these experimental models could be 
different. For example, even though RIPK1 kinase-deficient mice exhibited high viral 
titers following ZIKV infections, similar results were not observed in BMDM s or 
DCs after infecting with ZIKV (88).   
How RIPK1 inhibition might benefit the virus over the host should also be more 
fully addressed. For example, necroptosis and inflammatory signaling regulated by 
RIPK1 may control viral replication but could be deleterious to the host and contribute 
to disease pathogenesis. For example, necroptosis following IAV infection has been 
speculated to contribute to pulmonary tissue damage and acute respiratory distress 
syndrome (ARDS) (113). At this point, however, there is still a limited understanding 
of specific effects of RIPK1 inhibition in disease pathogenesis during viral infections. 
Overall, in this review, we discussed various strategies exploited by viruses to 
inhibit RIPK1-mediated signaling. Viral modulation of RIPK1-mediated signaling 
may lead to inhibition of NF-𝛋	B responses, MAPK signaling, IFN induction and cell 
death mechanisms. It is likely that most viruses benefit by inhibiting these pathways 
because in vivo viral replication increases by RIPK1 inhibition. Understanding the 
impact of inhibition of RIPK1 signaling on the host and the virus may facilitate the 
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Dengue virus (DENV) infection is the most prevalent arthropod-borne virus 
disease which is endemic in more than 100 countries. Several DENV proteins have 
been shown to target crucial host proteins to evade innate immune responses in order 
to establish a productive infection in humans. Here we report that the DENV protease, 
NS3, targets RIPK1 (Receptor Interacting Protein Kinase I), a central mediator of 
inflammation and cell death, and decreases intracellular protein levels during DENV 
infection. Furthermore, the decrease in RIPK1 protein results in the inhibition of 
TNFR- and TLR3-induced NF-𝛋B activation. Our data demonstrate a novel 
mechanism by which DENV suppresses normal cellular functions to evade host innate 




 Dengue virus infections are a major global health concern and approximately 3 
billion people are at risk of infection. Dengue virus is able to establish successful 
infections in humans by evading host innate immune mechanisms. Understanding 
these evasion strategies would be helpful for designing effective therapeutics against 
dengue infection and disease. Here we report a novel target of Dengue virus, RIPK1. 
Dengue viral protease interacted with and decreased levels of RIPK1, disrupting the 
NF-𝛋B signaling pathway involved in multiple innate immune responses. Our study 





 Dengue is the most prevalent arthropod-borne viral disease, with an estimated 
400 million infections occurring annually (1). Infected individuals may develop severe 
symptoms leading to dengue hemorrhagic fever (DHF), dengue shock syndrome 
(DSS), and even death. The causative agent of dengue, dengue virus , is known to 
infect dendritic cells, macrophages, monocytes, B cells, T cells, hepatocytes, epithelial 
and endothelial cells (2–4). The magnitude of DENV replication and its regulation of 
immune responses contribute to the disease pathogenesis. Effective antiviral drugs and 
vaccines are not available to treat the dengue disease, which emphasizes the 
importance of understanding DENV-host interactions (5). DENV refers to a group of 
four closely related positive-sense, single-stranded RNA viruses or serotypes (DENV 
1, 2, 3, 4), belonging to the Flaviviridae family. Upon entry into the host cell, the 
released viral genome is translated into one polypeptide, which gets cleaved into 
individual structural (capsid, PrM, and envelope) and non-structural proteins (NS1, 
NS2A, NS2B, NS3, NS4A, NS4B, NS5) by the viral protease complex, NS2B3, and 
host proteases (6). The individual DENV proteins generated are known to interact with 
numerous host proteins and interfere with host antiviral immune responses. DENV 
protease NS3 interacts with and cleaves STING and downregulates RLR (RIG-I like 
receptors) signaling (7). DENV protease also cleaves the mitochondrial proteins 
MFN1 and MFN2 and thereby impairs mitochondrial dynamics as well as efficient 
RLR signaling (8). 
 RIPK1 has emerged as an important regulator that controls multiple cellular 
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pathways involved in inflammation and cell death (9). RIPK1 is involved in innate 
immune responses to bacterial and viral infections by inducing apoptosis or 
necroptosis or by inducing inflammatory signaling (10). Activation of death receptors 
such as TNFR1 leads to the formation of a multi-protein complex including RIPK1, 
complex I, which facilitates the activation of NF-𝛋B and MAPK pathways to promote 
cell survival by inducing anti-apoptotic gene expression and the induction of 
proinflammatory cytokine gene expression (11).  The scaffolding function of RIPK1 is 
critical for NF-𝛋B activation.  RIPK1 is also involved in mediating TRIF-dependent 
TLR3- and TLR4-induced NF-𝛋B activation (12,13). RIPK1 can drive extrinsic 
apoptosis by activating caspase-8 via the formation of a distinct multi-protein 
complex, complex IIa (14), and can drive signaling to necroptosis through formation 
of a complex with RIPK3 (complex IIb) (15,16). RIPK1 also has been shown to 
regulate IRF3 transcription downstream of RIG-I/ MDA-5 complexes in response to 
RNA viruses (17). These pathways are crucial for mounting innate immune responses 
during viral infections. This central role of RIPK1 makes it an ideal target for 
inhibition by viruses, as has been shown for HIV-1 (18), human Rhinovirus 3C (19), 
and Epstein-Barr virus (20). However, no association between RIPK1 and DENV 
infection has been reported to date. Therefore, the objective of this study was to 
evaluate the effect of DENV infection on RIPK1 signaling. We show that RIPK1 is 
targeted by DENV protease NS3, which results in decreased RIPK1 protein levels 








RIPK1 protein levels decrease with DENV infection 
DENV is known to infect hepatocytes and the liver is one of the major organs 
affected during DHF (21). We tested the effect of DENV infection on the human 
hepatoma cell line, Huh7. A time-course analysis of DENV2 infection revealed a 
reduction in intracellular RIPK1 protein concomitant with the expression of DENV 
NS3 as early as 6h post-infection (Fig 1A). In order to see if this was a general effect, 
we infected cell lines originated from different human tissues with DENV2 as well as 
monocyte-derived dendritic cells (MoDC), which is a relevant primary cell system 
(22). We observed a significant decrease in endogenous RIPK1 protein levels with 
DENV2 infection in all the cells tested (Fig 1B). Overexpressed Flag-tagged RIPK1 
was also decreased in a dose-response manner in DENV2-infected HEK 293T cells 
(Fig 1C). This effect was specific for RIPK1 since endogenous or overexpressed 
RIPK3 levels were not affected by DENV infection (Fig 1D). Different strains of 
DENV1 and DENV2 decreased RIPK1 significantly in Huh7 cells; however, no 
significant decrease was observed in cells infected with several strains of DENV3 or 
DENV4 (Fig 1E & F).  
Next, we investigated if DENV inhibited RIPK1 at a transcriptional level. A 
time-course study was done with DENV2 infection in Huh7 cells. We did not see a 
decrease in RIPK1 transcript levels, indicating that the downregulation of RIPK1 




RIPK1 is reduced by DENV protease   
Negative regulation of RIPK1 by caspase 8 is well known. During activation of 
death receptors, active caspase 8 cleaves RIPK1 in the intermediate domain at Asp 324 
(23). Therefore, we first tested if active caspase 8 plays a role in decreasing RIPK1 
levels during DENV infection. Caspase 8 inhibition by zVAD-FMK was not sufficient 
to restore the decreased RIPK1 levels during DENV infection (S1). These data suggest 
that the decrease in RIPK1 in DENV-infected cells is not a result of cleavage by 
caspase 8. 
RIPK1 is known to be targeted by several viral proteases to counteract its 
functions and enhance viral replication (18,19). Therefore, to evaluate the mechanism 
of RIPK1 reduction during DENV infection, we tested whether expression of the 
DENV NS2B3 protease complex was sufficient to reduce RIPK1 levels. We co-
transfected a Flag-tagged RIPK1 and a plasmid encoding DENV NS2B3. We observed 
a dose response in RIPK1 reduction with the expression of DENV NS2B3 (Fig 2A, 
2B). However, we did not detect the accumulation of a cleaved product of RIPK1 
using antibodies targeting either the C-terminal or N-terminal segment of RIPK1. In 
order to determine if the protease activity was important for this effect, we created a 
catalytically inactive protease mutant, NS2B3-S135A (S2, (24)) Transfection of 
NS4B5-GFP, a target of DENV protease, confirmed the lack of protease activity of the 
mutant NS2B3 construct (25). Levels of neither endogenous nor overexpressed RIPK1 
were affected upon transfection of NS2B3-S135A, demonstrating that protease 
activity of NS2B3 was required for the reduction of RIPK1 levels (Fig 2C).  
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In order to evaluate if the reduction in RIPK1 is due to a direct effect of 
NS2B3 on RIPK1, we next performed co-immunoprecipitation experiments to detect a 
physical interaction between RIPK1 and NS2B3. HEK 293T cells were co-transfected 
with a Flag-tagged RIPK1 plasmid and a plasmid expressing either V5-tagged wild 
type (WT) DENV NS2B3 or NS2B3-S135A. DENV NS3 protein co-
immunoprecipitated with RIPK1 when pulled down with anti-Flag (Fig 2D, lane 3). 
As expected, the reciprocal immunoprecipitation using anti-V5 antibodies confirmed 
this interaction. Strikingly, a physical interaction between RIPK1 and NS2B3-S135A 
was also detected using specific antibodies (Fig 2D, lane 4). This suggests that NS3 
protease activity was not required for this protein-protein interaction even though it 
was necessary for decreasing RIPK1 levels (Fig 2C). We then validated the interaction 
of RIPK1 and NS3 in the context of DENV infection. HEK 293T cells transiently 
expressing Flag-RIPK1 were infected with DENV2 for 48hrs, then RIPK1 was 
immunoprecipitated using an anti-Flag antibody. We detected DENV NS3 bound to 
RIPK1 by western blot analysis (Fig 2E lane 2). We performed the reciprocal 
immunoprecipitation using an anti-DENV NS3 antibody and detected RIPK1 bound to 
DENV-NS3 by western blot analysis, verifying the interaction (Fig 2E).  
 
DENV impairs TNFR- and TLR3-induced NF-𝛋B activation  
RIPK1 is an adapter molecule downstream of TNFR and TLRs and plays an 
important role in downstream signaling leading to NF-𝛋B activation (3). Having 
established that DENV NS3 decreases RIPK1, we examined whether the loss of 
RIPK1 disrupts NF-𝛋B activation during DENV infection. First, in order to test how 
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NF-𝛋B activation is affected downstream of TNFR, Huh7 cells were transfected with 
a plasmid encoding a luciferase gene driven by NF-𝛋B response elements and a 
plasmid expressing Renilla luciferase as a control. Cells were stimulated with TNFɑ 
either prior to or after DENV infection. Cells were cultured for 48hrs post-infection 
and the luciferase activity was measured as described in Methods. NF-𝛋B activation in 
response to TNFɑ was significantly attenuated in DENV-infected cells as compared to 
uninfected cells when TNFɑ was added either before or after infection (Fig. 3A). We 
then assessed NF-𝛋B luciferase activity in response to TNFɑ stimulation with 
overexpression of RIPK1 in HEK 293T cells. NF-𝛋B luciferase activity was 
significantly reduced with DENV infection but this was restored by overexpression of 
RIPK1 (Fig 3B).  
We then examined the effect of DENV infection on NF-𝛋B activation in 
response to TLR3 stimulation. HEK 293T cells stably expressing TLR3 were 
transfected with the luciferase reporter plasmids with or without the Flag-RIPK1 
plasmid and then infected with DENV (MOI=3). They were further stimulated with 
poly I:C for 24hrs and luciferase activity was measured. DENV infection impaired 
poly I:C-induced NF-𝛋B activation relative to uninfected cells (Fig 3C). 
Overexpression of RIPK1 increased NF-𝛋B activity in both uninfected and DENV-
infected cells. However, even with RIPK1 overexpression, there was a significant 
decrease in NF-𝛋B activity in the presence of DENV relative to uninfected cells (Fig 
3C). These results demonstrate that DENV infection impairs NF-𝛋B activation 
downstream of both TNFR and TLR3 by decreasing RIPK1 protein levels.  
We further investigated if DENV NS2B3 downregulated NF-𝛋B activation by 
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targeting RIPK1. NF-𝛋B luciferase assays were performed with co-transfection of 
Flag-RIPK1 and WT NS2B3 or NS2B3-S135A. Increased NF-𝛋B activity due to 
overexpression of RIPK1 was attenuated by expression of WT NS2B3 but not by 
NS2B3-S135A (Fig 3D). These data indicate that expression of DENV NS2B3 is 
sufficient to inhibit NF-𝛋B activation by RIPK1, but that the physical interaction 







Figure 1. Endogenous and overexpressed RIPK1 decreases during DENV 
infection. (A) Time course study of DENV2 infection in human Huh7 cells with MOI 
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of 1 and 3 for the indicated hrs. Cell lysates were harvested for western blot analysis 
using the indicated antibodies. (B) Western blot analysis of RIPK1 in indicated cells 
infected with DENV2 (MOI=2) and cultured for 48hrs. 𝛃-actin was used as a loading 
control. (C) Western blot analysis of overexpressed RIPK1 and (D) RIPK3 followed 
by DENV2 infection in HEK 293T cells at 48h post-infection. (E) Western blot 
analysis of Huh7 cells infected with different DENV strains for 48 or 72 hrs and 
probed with antibodies to RIPK1 and DENV NS3. (F) RIPK1 band intensities at 72hrs 
p.i. were normalized to 𝛃-actin and were quantified by Image Lab software from 3 
independent experiments. Data are mean ± SD and were compared by Student’s t test 
(GraphPad Prism 8). (G) RT-qPCR analysis of total RNA isolated from Huh7 cells 
infected with DENV2 (MOI=2) for (G) RIPK1or (H) intracellular DENV RNA for the 
indicated time points. Data are mean ± SD (n=2 experiments) and were compared by 
Student’s t test (GraphPad Prism 8). Western blots are representative data from a 





Figure 2. DENV NS3 protease interacts with and decreases RIPK1. (A) Western 
blot analysis of HEK 293T cells co-transfected with Flag-RIPK1 and increasing 
concentrations of a plasmid expressing the DENV NS2B3 protease complex. (B) 
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Densitometric analysis of RIPK1 band intensities normalized to β-actin levels. Results 
are from a single experiment and are representative of at least three separate 
experiments. (C) Western blot analysis of HEK 293T cells co-transfected with Flag-
RIPK1 and plasmids expressing either WT NS2B3, NS2B3-S135A or an empty vector 
(pcDNA) and cultured for the indicated times. (D) Co-immunoprecipitation analyses 
of HEK 293T cells transiently overexpressing Flag-RIPK1 and WT NS2B3 or NS2B3-
S135A DENV protease complexes. (E) Co-immunoprecipitation analyses of HEK 
293T cells transfected with Flag-RIPK1 and mock (media) or DENV (MOI=1) 







Figure 3. TNFα- and poly(I:C)-driven NF-𝛋B activation is impaired during 
DENV infection. (A) NF-𝛋B luciferase activity was assessed in Huh7 cells co-
transfected with a NF-𝛋B luciferase reporter and a control Renilla luciferase reporter 
plasmid and stimulated with hTNFα (50ng/ml) before or after DENV2 infection and 
cultured for 48hrs  (B) HEK 293T cells were co-transfected with NF-𝛋B luciferase 
reporter, Renilla luciferase reporter and Flag-RIPK1 followed by DENV2 infection 
(MOI=3). Following TNFα (50ng/ml) treatment for 24hrs, cells were lysed, and 
luciferase activity was measured at 72hrs post-infection. (C) NF-𝛋B luciferase activity 
was assessed in HEK 293T-TLR3 cells as in (D) and cells were stimulated with poly 
(I:C) 20µg/ml for 24hrs before cell lysis. (D) HEK 293T cells were co-transfected 
with NF-𝛋B luciferase reporter, Renilla luciferase reporter, and Flag-RIPK1 along 
with WT DENV NS2B3 or NS2B3-S135A. Luciferase activity was detected at 48hrs 
post-transfection. Results are representative of at least three independent experiments 
and are expressed as mean ± SD from three biological replicates. (One-way ANOVA, 







Figure S1. Caspase 8 does not contribute to RIPK1 decrease in DENV infection. 
Western blot analysis of RIPK1 levels in HUH7 cells with inhibition of caspase 
activity by zVAD-FMK or treated with DMSO or Staurosporine following 42hrs of 
DENV2 infection. 
 
Figure S2. DENV NS2B3-S135A lacks protease activity. Western blot analysis of 
HEK 293T cells transfected with WT NS2B3 or NS2B3-S135A along with a substrate 
(NS4B5) for protease activity. Cell lysates were harvested 48hrs post-transfection and 




RIPK1 is a critical regulator of cell death and inflammation, and acts as an 
important adapter protein downstream of several receptors including TNFR, TLR3, 
TLR4, and RIG-I (26). Recently an anti-viral role of RIPK1 has emerged as it is 
involved in modulating an inflammatory form of cell death, necroptosis, and is also 
implicated in modulating NF-𝛋B and IFN responses (17,27,28). Therefore, we 
investigated the role of RIPK1 in DENV infection. We observed a pronounced 
reduction of RIPK1 during DENV infection in multiple cell types, including primary 
monocyte-derived dendritic cells. This effect could be reproduced by expression of the 
functionally active DENV protease, NS3. Furthermore, we demonstrated an inhibitory 
effect of DENV infection on NF-𝛋B activation in response to TNFɑ and poly I:C by 
targeting RIPK1.  
 DENV is known to target host proteins to evade host innate immune responses. 
DENV NS5 protein is involved in degrading STAT2 to interfere with IFN responses 
(29). DENV protease complex NS2B3 interacts with and cleaves STING and 
downregulates the RLR pathway (7). DENV protease is also involved in cleaving 
mitochondrial proteins MFN1 and MFN2 and thereby impairs mitochondrial dynamics 
as well as efficient RLR signaling (8). Previous findings also show that protease 
cofactor NS2B interacts with cGAS and promotes it for autophagosome-mediated 
degradation (30). These strategies serve to enhance viral replication. 
 Our findings add RIPK1 to the list of host proteins targeted by the DENV 
protease. Targeting of RIPK1 has the potential to give an added advantage to the virus 
since RIPK1 mediates several crucial signaling pathways. RIPK1 has an N terminal 
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kinase domain, a RHIM (RIP homotypic interaction motif) containing intermediate 
domain, and a C terminal death domain (DD). RIPK1 binds to the DD of FADD, 
TNFR1, TRADD (31–33). The RHIM domain of RIPK1 mediates interactions with 
other RHIM containing proteins such as RIPK3, TRIF, and ZBP1 (13,34,35). Here, we 
observed a physical interaction between RIPK1 and DENV NS3. There may be other 
proteins involved in this NS3-RIPK1 complex. The domains and motifs of DENV 
NS3 and RIPK1 important for this interaction have to be determined. There have been 
a few published studies and databases on DENV-human protein-protein interactions 
(36,37), but none reported RIPK1 as a target of DENV protease, NS3. This could be 
due to the fact that endogenous RIPK1 remains undetected for Mass Spectrometry due 
to the significant reduction in protein levels by DENV.  
Caspase 8 is known to negatively regulate RIPK1 by cleaving it following the 
induction of extrinsic apoptosis (23). However, decreased RIPK1 levels were seen 
during DENV infection even with inhibition of caspase 8 (S1). Furthermore, RIPK1 
was not inhibited at the transcriptional level by DENV (Fig 1H). Interestingly, the 
catalytic activity of NS2B3 was important for RIPK1 reduction since catalytically 
inactive mutant NS2B3-S135A did not decrease RIPK1 efficiently. However, we were 
not able to detect a cleaved/degraded product of RIPK1 using either C-terminal or N-
terminal targeting antibodies. These data suggest that the product of cleavage by 
NS2B3 is too small to detect or could have been further degraded rapidly by other 
cellular mechanisms such as proteasome-mediated or lysosome-mediated degradation. 
Nevertheless, we hypothesize that NS2B3 plays a direct role in decreasing RIPK1 
levels based on the evidence of a physical interaction of DENV NS3 and RIPK1. The 
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NS2B3-S135A mutant also interacted with RIPK1 demonstrating that the catalytic site 
is not required for this interaction. Similarly, both the active and inactive NS2B3 
interacted with STING but only the active protease was able to effectively decrease its 
levels (7).  
Increased serum TNFɑ levels have been reported in patients with dengue (38). 
The interaction of TNFɑ and TNFR1 results in the formation of complex I leading to 
NF-𝛋B activation (39). NF-𝛋B transcription factors regulate a large number of genes 
involved in immune responses. Therefore, signaling leading to NF-𝛋B activation 
serves as an anti-viral immune mechanism. Viruses inhibit NF-𝛋B pathway activation 
to evade these host immune and inflammatory responses (40). DENV infection was 
shown to block NF-𝛋B activation downstream of TLR signaling resulting in 
downregulated cytokine production (41). Similar studies in Huh7 and monocyte-
derived macrophages showed that DENV infection altered cellular responses to TNFɑ 
stimulation (42). However, the mechanism by which DENV caused these altered 
responses had not been defined. We demonstrated that DENV infection diminished 
NF-𝛋B activation in response to TNFɑ or poly I:C stimulation and that NF-𝛋B 
promoter activity drastically increased when RIPK1 was overexpressed both in the 
presence and the absence of DENV infection. We also demonstrated that increased 
NF-𝛋B luciferase activity in response to the over-expression of RIPK1 was 
significantly decreased with the over-expression of WT NS2B3 but not with NS2B3-
S135A. Together these results show that the levels of RIPK1 are critical for regulating 
upstream signals leading to NF-𝛋B activation and that DENV infection dampens NF-
𝛋B transcription by targeting RIPK1. 
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Liver injury is a common finding in DENV infection and can lead to organ failure. 
Apoptosis of hepatocytes following DENV infection is believed to contribute to this 
phenomenon (21). Recent findings show a protective role of RIPK1 in TNFɑ-mediated 
apoptosis in hepatocytes (43,44). RIPK1 knockout mice showed enhanced sensitivity 
to TNFα-mediated apoptosis and inflammation. Induction of NF-𝛋B target gene 
transcripts was also suppressed in these mice. Therefore, we speculate that loss of 
RIPK1 during DENV infection may sensitize hepatocytes to cell death and 
inflammation, which could contribute to liver injury in DHF. We observed differences 
between DENV strains in their effect on RIPK1 levels. These differences could relate 
to differences in protease structures and might contribute to differences in disease 
manifestations but further analysis would be required to establish those associations 
(45–47)  
To the best of our knowledge, this is the first description of DENV targeting 
RIPK1. This is also the first report of inhibition of NF-𝛋B signaling by the DENV 
protease NS2B3 by targeting RIPK1. These findings open up new research directions 
on the interplay of DENV with various emerging functions of RIPK1. Further studies 
are required to shed light on cell- and context-dependent effects of RIPK1 reduction in 
vivo during DENV infection. Finally, we believe that these data expand knowledge of 
strategies used by DENV to evade innate immune responses.  
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Materials and methods  
Cell culture and virus infection  
Huh7, HEK 293T cells stably expressing TLR3 ( generous gifts from Dr. Kate 
Fitzgerald), HEK 293T (Dharmacon, Inc.) Vero, Huh 7.5 (obtained from American 
Type Culture Collection (ATCC)) were maintained in Dulbecco's modified minimal 
essential medium and HepG2 (ATCC) cells were maintained in Eagle's Minimum 
Essential Medium, supplemented with 10% heat-inactivated fetal bovine serum 
(Sigma-Aldrich), 1% penicillin-streptomycin (Sigma-Aldrich), 1% non-essential 
amino acids (Lonza) and 1% L-Glutamine solution (Sigma-Aldrich). All cells were 
incubated in a humidified chamber at 37 °C and 5% CO2. Prototype DENV strains 
DENV1 Hawaii, DENV1 CO245/96, DENV2 16681, DENV2 New Guinea C (NGC), 
DENV3 CH53489, DENV3 CO360,  DENV4 814669 and DENV4 H241 were 
originally obtained from the American Type Culture Collection , the Walter Reed 
Army Institute of Research or Armed Forces Research Institute for Medical Sciences 
(Bangkok, Thailand), and were passaged multiple times in C6/36 cells (ATCC, USA). 
Virus titers were determined by immunostained plaque assay on Vero cells (25,48). 
Generation of MoDCs  
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coat of healthy 
donors obtained from Oklahoma Blood Institute (Oklahoma City, OK) by density 
gradient centrifugation on Ficoll- Paque Premium (GE Healthcare). Monocytes were 
isolated from PBMCs by positive selection using CD14+ microbeads (Miltenyi 
Biotec). Monocytes were cultured in RPMI 1640 medium supplemented with 10% 
heat-inactivated FBS (Sigma-Aldrich), 1% penicillin- streptomycin (Sigma-Aldrich), 
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50 ng/mL human interleukin-4 (IL-4) and 160 ng/mL human granulocyte-macrophage 
colony-stimulating factor (GM-CSF) for 5 days to generate monocyte-derived 
dendritic cells (MoDCs). Fresh medium with cytokines was added at day 3, and cells 
were infected with DENV2 at day 5.  
Antibodies and reagents  
The following primary antibodies were used for  co-immunoprecipitation and western 
blot experiments: anti-Flag-HRP (sc-166355, Santa Cruz Biotechnology), mouse anti-
RIPK3 (sc-374639, Santa Cruz Biotechnology), anti-β-actin-HRP (ab20272, Abcam), 
anti-V5 tag (ab27671,  Abcam), anti V5-HRP (R961-25, Invitrogen), anti-GAPDH-
HRP (MA515738) anti-DENV NS3 (GTX124252, GeneTex), anti-DENV NS4B 
(GTX103349, GeneTex), anti-RIPK1 (D94C12, Cell Signaling Technology) and 
mouse anti-DENV2 (MAB8702, EMD Millipore). Secondary antibodies used were 
goat anti-rabbit-HRP (32260, Thermo Scientific), anti-mouse-HRP (sc516102, Santa 
Cruz Biotechnology).  
Caspase 8 inhibition 
HUH7 cells were infected with DENV2 (MOI=1) and cultured for 48hrs. Cells were 
treated with 10µM-40µM of a pan caspase inhibitor; z-VAD-FMK (SC-3067, Santa 
Cruz Biotechnology) or DMSO (BP231-100, Fisher Scientific) or 1 µM of 
Staurosporine (S4400, Sigma Aldrich) for 6hrs before cell lysis. 
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Western Blot analysis  
Cells were lysed in RIPA buffer freshly supplemented with a protease and phosphatase 
inhibitor cocktail (Sigma aldrich). Lysates were incubated on ice for 30 min with 
vortexing every 5 minutes and centrifuged at 10,000 rpm for 5 min at 4 °C. 
Supernatants were used as total cell lysates. Protein concentrations were determined 
using Pierce BCA Protein Assay kit (Thermo Fisher Scientific) following 
manufacturer's instructions and measured using an Envision plate reader 
(PerkinElmer). BOLT LDS Sample Buffer and Reducing Agent (Thermo Fisher 
Scientific) were added to cell lysates at a final concentration of 1x and samples were 
denatured at 70 °C for 10 min. Proteins were separated on 4–12% or 8% BOLT Bis-
Tris Plus gel (Thermo Fisher Scientific) and transferred onto nitrocellulose membranes 
using the Trans-Blot® TurboTM RTA Mini Nitrocellulose Transfer kit (Bio-Rad). 
Membranes were blocked in 5% milk in phosphate buffered saline with 0.1% Tween 
20 for 1 h at room temperature (rt) followed by incubation with the appropriate 
primary antibody overnight at 4 °C. Membranes were washed and incubated with the 
appropriate secondary antibody diluted in blocking buffer for 1 hour at rt. For β-actin 
and GAPDH analysis, membranes were stained for 1 hour with corresponding 
antibodies. Detection of blots was done using Amersham ECL Select Western Blotting 
Detection Reagent (GE Healthcare Life Sciences) following the manufacturer's 
guidelines and images were captured with ChemiDocTM XRS+ System (Bio-Rad). 




Cells were lysed with RIPA buffer containing a cocktail of protease and phosphatase 
inhibitors. Protein G dynabeads (Thermo Fisher Scientific) were incubated with either 
mouse anti-Flag (Santa Cruz), mouse anti-V5 (abcam) or mouse anti NS3 (Genetex) 
for 1 hr at rt. Then, cell lysates were incubated with antibody-coated beads overnight 
at 4°C. The immunocomplex was eluted under denaturing conditions according to the 
manufacturer’s recommendations, and then examined by Western blot analysis.  
Plasmids, and transfections  
The following plasmids were used in our study: pNS4B5-eGFP, pNS2B3-V5 (16). 
pNS2B3-S135A was created by site-directed mutagenesis (Quik Change II site-
directed mutagenesis kit, Agilent Technologies) using WT NS2B3 plasmid. The 
plasmid sequence was verified by DNA sequencing. Plasmids expressing Flag-RIPK1 
and RIPK3-GFP were obtained from Addgene. The luciferase reporter constructs 
containing a tandem repeat of the consensus binding site for the transcription factor 
NF-𝛋B, and a Renilla reniformis luciferase were obtained from Strategene. 
Transfection of cells with plasmids was performed using GeneJuice® Transfection 
Reagent (EMD Millipore), according to the manufacturer's instructions.  
RT-qPCR analysis  
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Total RNA was extracted from cell pellets using the RNeasy Mini Kit (Qiagen). 
Quantitative RT- PCR was performed using iTaq Universal probes 1 step kit (Biorad) 
or iTaq Universal SYBR Green 1 step kit (Biorad) on a Bio-Rad CFX machine, and 
gene expression was normalized to β-actin expression level. Taqman gene expression 
assays (RIPK1) were purchased from Thermofisher Scientific. DENV primers were 
purchased from Integrated DNA Technology (IDT) and RT-qPCR was performed to 
detect relative DENV RNA in cell lysates (40). 
Luciferase reporter assays 
HEK 293T cells were plated in 96 well plates and were co-transfected with a NF-𝛋B 
luciferase reporter, a Renilla luciferase reporter and, and a plasmid encoding Flag-
tagged RIPK1 using GeneJuice® Transfection Reagent (EMD Millipore), according to 
the manufacturer’s protocol. Co-transfected cells were infected with DENV2 (NGC, 
MOI=3) and were cultured for 72hrs and were stimulated with hTNFɑ (50ng/ml). 
Luciferase activity was quantified using the dual Glo luciferase assay system 
(Promega). HEK 293T cells stably expressing TLR3 were co-transfected and infected 
with DENV as described above and were stimulated with poly I:C (20µg/ml) for 
24hrs. At the end of the treatment, luciferase activity was measured using the dual Glo 
luciferase assay system (Promega).  
Statistical analysis 
The statistical analyses were performed using one-way analysis of variance (ANOVA), 
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with Tukey’s methods or the unpaired, two-tailed, Student’s t-test. P values were 
calculated using Graphpad Prism 8 program. Differences were considered statistically 
significant at P values less than 0.05.  
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Additional mechanisms and implications of RIPK1 downregulation by DENV 
 
 
DENV does not mediate RIPK1 degradation via proteasomes or lysosomes 
 
Introduction 
The ubiquitin-proteasome and the autophagy-lysosome pathways are the two 
major-protein degradation routes in eukaryotic cells (1). Proteasomes are barrel-
shaped multi protein complexes that mediate degradation of short-lived and misfolded 
proteins (2). Most proteins are covalently modified with ubiquitin (Ub) before they are 
targeted for proteasomal degradation. Usually, three enzymes; ubiquitin-activating 
(E1), ubiquitin-conjugating (E2) and ubiquitin-ligating (E3), are involved in this 




Figure 1. Schematic diagram of the ubiquitin-proteasome system. Specific 




There is evidence of DENV targeting the proteasome pathway to degrade key 
host proteins to evade host immune responses. The reduction in STAT2 protein levels 
by the DENV NS5 protein was blocked by treatment with the proteasome inhibitor, 
MG-132, indicating that intact proteasome activity was required for the STAT2 
reduction (4). DENV NS2B3 cleaved mitochondrial proteins MFN1 and MFN2, and 
the cleaved fragments were further degraded by host proteasome machinery (5).  
 The degradation of cytoplasmic proteins or organelles via the lysosome is 
predominantly mediated by autophagy (6). This process involves the formation of 
autophagosomes/ autophagic vacuoles surrounding the proteins to be degraded (Fig 2). 
These vacuoles fuse with lysosomes to form autophago-lysosomes. The interior 
contents of autophago-lysosomes then get degraded by acidic lysosomal hydrolases. 
The cytosolic protein LC3-II, which is derived from LC3-I, is recruited to the outer 
membrane of the developing autophagosome and plays a major role in autophagosome 
elongation. Therefore, LC3-I to LC3-II conversion and LC3-II degradation detected 
by western blotting is used as a marker for autophagy (7). DENV has been shown to 
increase protein degradation via the autophagy-lysosome pathway. DENV protease co-
factor NS2B interacted with and promoted autophagosome-mediated degradation of 
cGAS, which is a key component in the DNA sensing pathway (8). cGAS protein 
levels in the presence of NS2B increased upon treatment with an autophagy inhibitor 
(3MA) or lysosome inhibitors (Chloroquine/CLQ, NH4Cl).  
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Figure 2. Schematic diagram of the autophagy-lysosome pathway with specific 
inhibitors. Upon initiating by PI3K, autophagosomes containing specific 
molecules/proteins to be degraded fuse with lysosomes. Lysosomal enzymes then 
degrade the contents in the autolysosome enabling recycling of nutrients. 3MA 
specifically inhibits autophagosome formation. Chloroquine and Bafilomycin A1 
inhibit autophagosome-lysosome fusion. NH4Cl alters the pH in the autolysosome 
inhibiting enzymatic activation. 
 When RIPK1 is K48 poly-ubiquitinated by cIAP1/2 (cellular inhibitor of 
apoptosis 1/2) downstream of TNFR1, it is degraded via the proteasome (9). RIPK1 
can also be degraded via the lysosome by CHIP E3 ligase-mediated ubiquitylation 
(10). Since we detected decreased RIPK1 levels with DENV infection, we 
hypothesized DENV may promote RIPK1 degradation via proteasomal/lysosomal 
degradation pathways. 
 
Results and Discussion 
In order to test if RIPK1 is degraded by proteasomal/lysosomal degradation 
machinaries, Huh7 cells were infected with DENV2 (MOI=0.2 or MOI=1) for 24 hrs. 
Cells were then treated with MG132, CLQ, or the vehicle control, DMSO, for 24hrs, 
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and the cell lysates were analyzed by western blotting (Fig. 3). As expected, based on 
the results presented in Chapter 2, RIPK1 levels significantly decreased with DENV2 
infection. However, the RIPK1 levels did not recover with the inhibition of either the 
proteasome or the lysosome pathways. Chloroquine treatment clearly increased the 
LC3-II levels indicating efficient inhibition of lysosomal function (Fig 3 lanes 7-9).  
Taken together these data suggest that RIPK1 is not subjected to these cellular 
degradation machineries by DENV.  
We were not able to detect a cleaved/degraded product following the DENV 
NS3-dependent decrease of RIPK1 by using either an N-terminal targeting or a C-
terminal targeting antibody. It is possible DENV NS3 cleaves RIPK1, which still has 
to be resolved. Possibly the product of cleavage by NS2B3 is too small to detect or 
could have been further degraded rapidly by other cellular mechanisms such as 
proteasome-mediated or lysosome-mediated degradation.  However, inhibition of the 
proteasome by MG132 or Bortezomib treatment following NS2B3 overexpression did 
not increase RIPK1 levels nor did it reveal smaller size bands for RIPK1 (data not 
shown).  
We further investigated whether RIPK1 fragment(s) might be degraded via 
autophagy. In order to test this, we co-expressed RIPK1 and NS2B3 in cells cultured 
in the presence or absence of the autophagosome-formation inhibitor 3MA (11). 
Preliminary results demonstrated that RIPK1 levels still decreased in the presence of 
DENV NS3 despite 3MA treatment (Fig 4). Taken together these data suggest that 
RIPK1 was not degraded via either the proteasome or the lysosome after NS3-
mediated decrease. Therefore, it is possible that the resulting RIPK1 product/s from 
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NS3-mediated cleavage could be too small to detect by western blotting. However, 
further studies are needed to elucidate the complete mechanism. For example, 3MA 
doses could be optimized and additional markers such as LC3-II levels could be used 





 Figure 3. RIPK1 is not degraded via proteasomes or lysosomes during DENV 
infection. Huh7 cells were infected with DENV2 followed by proteasome and 
lysosome inhibition using MG132 or Chloroquine (CLQ), respectively. Cell lysates 
were harvested for western blot analysis using the indicated antibodies. GAPDH was 
used as a loading control. Representative data are shown from a minimum of 2 




Figure 4. RIPK1 is not degraded via autophagy following NS2B3 expression. 
Western blot analysis of RIPK1 levels following the inhibition of autophagy with 
3MA using the indicated antibodies. Expression and efficient cleavage of NS2B3 is 





DENV suppresses TSZ-induced necroptosis 
Introduction 
RIPK1 is involved in inducing cell death by necroptosis downstream of 
TNFR1, TLR3, and TLR4 (12). The kinase activity of RIPK1 is important for 
phosphorylation of RIPK3 (13). Phosphorylated RIPK3 in turn phosphorylates 
MLKL, which translocates to the plasma membrane (Fig 5). MLKL polymerizes itself 
and permeabilizes the plasma membrane, releasing PAMPs and DAMPs into the 
extracellular milieu. Other immune cells are then recruited to the site of necroptosis 
and initiate inflammatory responses (13). Necroptosis can be blocked by the RIPK1 
kinase inhibitor Necrostatin-1 (14). The most established experimental protocol for the 
induction of necroptosis involves signaling through TNFR1. Treatment with TNFα, 
Smac mimetic, and zVAD cocktail (T/S/Z) is known to cause necroptosis in numerous 
cells (15,16).  Smac mimetic antagonizes cIAP proteins and diverts TNFa signaling 
from NF-kB activation (17). Pan-caspase inhibitor zVAD then diverts signaling to 
induce necroptosis (18).  As RIPK3 phosphorylation at S227 and MLKL 
phosphorylation at T357/S358 are critical for the this process, pRIPK3/ pMLKL are 
used as markers for detecting the induction of necroptosis (19). In order to sustain cell 
survival and to inhibit inflammatory responses, viruses have evolved many strategies 
to counteract necroptosis. Viruses have evolved proteins that target and decrease 
RIPK1 levels or block RIPKI interaction with RIPK3 by competitive binding to 
RIPK1 (20,21). However, no investigations have been reported on necroptosis during 





Figure 5. RIPK1-mediated necroptosis induction. Upon stimulation of TNFR1, 
TLR3 or TLR4, RIPK1 interacts with RIPK3 and they mutually phosphorylate each 
other in a complex known as the “necrosome”. Phosphorylated RIPK3 phosphorylates 
MLKL. Phospho-MLKL translocates to the plasma membrane, polymerizes and 
compromises plasma membrane integrity by undefined mechanisms. 
 
Results and discussion 
We have observed cell condensation and fragmentation by microscopy in many 
cell lines following DENV infection, indicating cell death, especially after 24hrs. 
Since RIPK1 levels significantly decreased during DENV infection we hypothesized 
that necroptosis was not a major cause of DENV-induced cell death. In order to 
confirm this, we compared the cell viability in different cell lines after treating with 
the specific RIPK1 inhibitor, Necrostatin-1 (Nec1) or the vehicle control DMSO 
followed by DENV infection. Cell viability was significantly decreased by DENV. 
However, consistent with our hypothesis, Nec-1 treatment did not increase cell 
survival after DENV infection (Fig 6A-E). These data suggest that necroptosis does 
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not play a major role in DENV infection, perhaps to the benefit of the virus.  
Next, we hypothesized DENV will suppress induced necroptosis. Since not all 
cell types are sensitized to undergo T/S/Z-induced necroptosis, we first tested if 
human U937 cells stably expressing DC-SIGN undergo necroptosis upon T/S/Z 
treatment (16). U937-DC-SIGN cells treated with T/S/Z had less viability after 6hrs of 
treatment (Fig 6F). This effect was not due to apoptosis, since cleaved caspases were 
not detected (Fig 6F).  We next analyzed the level of T357/S358-phosphorylated 
MLKL as a marker for the induction of necroptosis. We detected a significant increase 
in p-MLKL in T/S/Z-treated U937-DC-SIGN cells, confirming it’s a good model to 
use for our studies (Fig 6F).  
Next, to test the effect of DENV on necroptosis we treated DENV2-infected 
and uninfected human U937-DC-SIGN cells with necroptosis inducers (T/S/Z) and/or 
RIPK1 inhibitor Nec-1. T/S/Z induced an increase in p-MLKL in uninfected U937-
DC-SIGN cells which was significantly suppressed by treatment with Nec-1. In 
contrast, p-MLKL was hardly detected in DENV-infected cells following T/S/Z 
treatment (Fig 6G-H). Taken together, these data indicate that DENV does not signal 
for necroptosis induction. Furthermore, DENV infection inhibits T/S/Z induced 
necroptosis (Fig 6G-H). However, in order to confirm in vivo responses, it would be 
better to investigate the effect of DENV on necroptosis induction downstream of 








Figure 6. DENV suppressed necroptosis. (A-E) Indicated cell lines were treated with 
Nec-1 or DMSO followed by DENV2 infection for 48hrs. Cell viability was measured 
by detecting ATP-producing cells with Cell Titer Glo assay. The viability of DMSO-
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TSZ, TSZ + Nec-1, or DMSO treatment for 6hrs, (G) U937-DC-SIGN cells were 
treated with DENV2 for 48hrs followed by TSZ, TSZ + Nec-1, or DMSO treatment 
for 6hrs. Cell lysates were analyzed by western blotting using the indicated antibodies. 













Disruption of innate immune responses may give pathogens an advantage for 
establishing infection. RIPK1 is a central mediator of many cellular signaling 
pathways that are important in innate immune responses. Therefore, RIPK1 is an 
attractive target for pathogens. As we showed in Chapter 2, many other viruses target 
and inhibit RIPK1-mediated signaling. There is evidence that inhibition of RIPK1-
mediated pathways can enhance viral replication.  For example, RIPK1 kinase 
activity-deficient mice had higher viral titers after infection with ZIKV and displayed 
greater susceptibility to WNV infection relative to wild type mice (22,23).  RHIM and 
IPAM domains  of MCMV M45 proteins were found to be important for inhibition of 
RIPK1-mediated necroptosis (24). MCMV expressing M45 deficient of RHIM and/ or 
IPAM displayed lower viral titers in mice possibly due to intact RIPK1-mediated 
signaling. In light of this evidence, we hypothesized that RIPK1 expression would 
have a deleterious effect on DENV replication. 
 
Results and discussion 
 
  Several approaches were used to investigate the effect of RIPK1 expression on 
DENV replication. First, we transfected a plasmid expressing Flag-RIPK1 in 
HEK293T cells and cultured for 24 hrs. We then infected RIPK1-overexpressing cells 
with DENV2. After an additional 48hrs supernatants from cells were collected. Cells 
were lysed and total RNA and total protein were extracted. Western blot assays were 
done to confirm RIPK1 overexpression and DENV infection. Total RNA was analyzed 
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by qRT-PCR to quantify relative intracellular DENV RNA. Supernatants were used for 
immuno-stained plaque assay (25) to determine the titer of infectious DENV particles.  
 Western blot results confirmed RIPK1 overexpression. However, we observed 
a decrease in overexpressed RIPK1 levels with DENV infection (Fig 7A lanes 5,6 & 
Fig 7B). We did not detect a difference in infectivity with overexpression of RIPK1 as 
shown by the intensity of bands corresponding to DENV NS3 (Fig 7A lanes 4,5,6). 
Relative intracellular DENV RNA levels increased by 69 hrs post-infection as 
compared to 20hrs post-infection even with the overexpression of RIPK1 (Fig 7C). A 
slight decrease in intracellular DENV RNA levels was observed with the 
overexpression of RIPK1 as compared to pcDNA control plasmid at both 20 hrs and 
69 hrs post-infection. Viral titers in the supernatants of cells where RIPK1 was 
overexpressed were also slightly lower than in supernatants of control cell cultures at 
20 hrs post-infection. However, neither of these differences (in intracellular viral RNA 
or viral titers) was statistically significant. 
 We next hypothesized further ablation of RIPK1 will benefit DENV 
replication. Thus, we next investigated the effect of endogenous RIPK1 expression on 
DENV replication. We transfected either a RIPK1-specific small interfering RNA 
(siRNA) or a scrambled siRNA as a control into HEK293T cells and subsequently 
infected the cells with DENV2 (MOI=2).  Cells were harvested and total RNA was 
extracted at 24 hrs post-infection. qRT-PCR was done on total RNA to detect RIPK1 
and DENV RNA levels. We observed ~ 70% reduction in RIPK1 transcript levels with 
siRNA treatment relative to controls (untreated and control siRNA-treated), 
confirming the efficient knockdown of RIPK1 (Fig 8A). However, we observed no 
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change in DENV RNA levels (Fig 8B). These preliminary results demonstrate that 
DENV replication is unaffected by RIPK1 knockdown. Experiments should be 
repeated to confirm this conclusion. 
Overall our results indicate that RIPK1 expression does not directly affect 
DENV replication in vitro. However, further studies are needed before an important 
effect can be excluded. Strikingly most of the evidence on increased viral replication 
with inhibition of RIPK1-mediated signaling is from in vivo studies. Daniels et al. 
observed higher viremia in mice deficient in RIPK1 following ZIKV infection, 
however, they could not reproduce these results in vitro (24). Neither genetic nor 
pharmacological ablation of RIPK1 had an impact on ZIKV replication in bone 
marrow-derived macrophages or dendritic cells. These results indicate the inhibition of 
RIPK1-mediated signaling has different effects on viral replication in vivo vs in vitro. 
However, we evaluated DENV replication without inducing RIPK1 signaling by 
adding external stimuli such as TNF⍺. Therefore, the effects of TNFR1 and TLR3 
signaling pathways on DENV replication could be investigated since these pathways 
are inhibited by DENV. DENV titers/ RNA could be measured upon TNF⍺ and poly 












Figure 7. DENV replication is not affected by RIPK1 overexpression. (A) Western 
blot results of HEK293T cells transfected with either a Flag-RIPK1 plasmid (0.25µg 
/0.75µg) or a pcDNA (0.75 µg) control plasmid followed by DENV2 infection. 
Overexpressed RIPK1 levels were detected by a ⍺Flag antibody while DENV 
infection was detected by probing with an ⍺NS3 antibody. β-actin was used as a 
loading control. Data are representative of a minimum of 3 experiments. (B) 
Densitometric analysis of RIPK1 band intensities normalized to β-actin levels from 
(A). Results are from a single experiment and are representative of at least three 
separate experiments. (C) RT-qPCR analysis of intracellular DENV RNA at 20 hrs and 
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69hrs post-infection. (D) Plaque assay of culture supernatants from DENV2-infected 
cells 20hrs following pcDNA or RIPK1 overexpression. Error bars represent standard 







Figure 8. DENV Replication is not affected by silencing of endogenous RIPK1. 
RT-qPCR analysis of total RNA isolated from HEK293T cells untransfected (UNT) or 
transfected with either a RIPK1-specific siRNA (RIPK1) or scrambled siRNA (-Ve) 
followed by DENV infection for (A) RIPK1 mRNA or (B) intracellular DENV RNA 









Materials and methods 
Cell culture and virus infection 
Huh7 ( a generous gifts from Dr. Kate Fitzgerald), HEK 293T (Dharmacon, Inc.) and 
Vero, (obtained from American Type Culture Collection (ATCC)) were maintained in 
Dulbecco's modified minimal essential medium and supplemented with 10% heat-
inactivated fetal bovine serum (Sigma-Aldrich), 1% penicillin-streptomycin (Sigma-
Aldrich), 1% non-essential amino acids (Lonza) and 1% L-Glutamine solution 
(Sigma-Aldrich). All cells were incubated in a humidified chamber at 37 °C and 5% 
CO2. Prototype DENV strains DENV2 16681 was originally obtained from the 
American Type Culture Collection. Virus titers were determined by immunostained 
plaque assay on Vero cells (25,26) 
Western Blot analysis  
Cells were lysed in RIPA buffer freshly supplemented with a protease and phosphatase 
inhibitor cocktail (Sigma-Aldrich). Lysates were incubated on ice for 30 min with 
vortexing every 5 minutes and centrifuged at 10,000 rpm for 5 min at 4 °C. 
Supernatants were used as total cell lysates. Protein concentrations were determined 
using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific) following 
manufacturer's instructions and measured using an Envision plate reader 
(PerkinElmer). BOLT LDS Sample Buffer and Reducing Agent (Thermo Fisher 
Scientific) were added to cell lysates at a final concentration of 1x and samples were 
denatured at 70 °C for 10 min. Proteins were separated on 4–12% or 8% BOLT Bis-
Tris Plus gels (Thermo Fisher Scientific) and transferred onto nitrocellulose 
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membranes using the Trans-Blot® TurboTM RTA Mini Nitrocellulose Transfer kit 
(Bio-Rad). Membranes were blocked in 5% milk in phosphate buffered saline with 
0.1% Tween 20 for 1 h at room temperature (rt) followed by incubation with the 
appropriate primary antibody overnight at 4 °C. Membranes were washed and 
incubated with the appropriate secondary antibody diluted in blocking buffer for 1 
hour at rt. For β-actin and GAPDH analysis, membranes were stained for 1 hour with 
corresponding antibodies. Detection of blots was done using Amersham ECL Select 
Western Blotting Detection Reagent (GE Healthcare Life Sciences) following the 
manufacturer's guidelines, and images were captured with the ChemiDocTM XRS+ 
System (Bio-Rad). Detection and quantification of band intensities were performed 
using Image Lab 5.1 (Bio-Rad). 
Antibodies 
The following primary antibodies were used for  western blot experiments: anti-Flag-
HRP (sc-166355, Santa Cruz Biotechnology), anti-Caspase 3 (sc-56053, Santa Cruz 
Biotechnology), anti-β-actin-HRP (ab20272, Abcam), anti-p-MLKL (ab187091, 
Abcam),  anti-GAPDH-HRP (MA515738), anti-DENV NS3 (GTX124252, GeneTex), 
anti-RIPK1 (D94C12, Cell Signaling Technology), and anti-LC3B (2775S, Cell 
Signaling Technology). Secondary antibodies used were goat anti-rabbit-HRP (32260, 
Thermo Scientific) and anti-mouse-HRP (sc516102, Santa Cruz Biotechnology).  
Plasmids and transfection 
Overexpression of RIPK1 was done by transfecting 0.25µg or 0.75µg of a Flag-RIPK1 
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plasmid (Addgene) or 0.75µg of a control plasmid (pcDNA) into HEK293T cells 
using Genejuice transfection reagent (EMD Millipore, cat# 70967-3) according to 
manufacturer’s protocols. siRNA targeting RIPK1 and siRNA negative control were 
purchased from ThermoFisher Scientific. Transfection of cells with siRNA was 
performed using Lipofectamine RNAiMAX transfection reagent according to the 
manufacturer's instructions (Thermofisher Scientific). 
 
Proteasome inhibition 
DENV2-infected or uninfected Huh7 cells were treated with 1µM MG132 for 24 hrs 
or 100nM Bortezomib for 6hrs. Control cells were treated with a similar concentration 
of DMSO. Cells were harvested and analyzed by western blotting. 
 
Autophagy inhibition 
Cells transfected with Flag-RIPK1 and DENV NS2B3 were treated with 3.3mM 3MA 
or an equal concentration of the vehicle control, EtOH, for 12 hrs. Cells were 
harvested and RIPK1 levels detected by western blotting. 
 
Lysosome inhibition 
DENV2-infected or uninfected Huh7 cells were treated with 10µM Chloroquine for 24 
hrs or 100nM Bortezomib for 6 hrs. Control cells were treated with a similar volume 




Cell viability assay  
Huh 7, Huh 7.5, Hek 293T and Vero cells were plated in a 96 well plate. Cells were 
pretreated for 1hr with 20µM Nec-1 or DMSO. After 1 hr cells were infected with 
DENV2 and cultured for 48hrs. Cells were then lysed by the addition of Cell titer Glo 
reagent (Promega) diluted 1:4 in Phosphate buffered saline (PBS). Cell lysates were 
transferred into a 96-well opaque plate and the luminescence was measured using an 
Envision plate reader (PerkinElmer). Values were averaged from 3 biological 
replicates and the values for uninfected DMSO-treated cells were defined as 100%. 
 
Necroptosis assay 
U937-DC-SIGN cells were plated in a 24-well plate and infected with DENV2 
(MOI=5) for 42hrs. Cells were then treated with 20µM zVAD-FMK (Santa Cruz 
Biotechnology), 50ng/ml TNF⍺ (Peprotech), and 10µM Smac mimetic (Fisher 
Scientific) with and without 50µM Nec-1 (Sigma Aldrich) for 6 hrs. Cells were 
harvested by centrifugation at 1600rpm for 5 minutes and lysed with RIPA buffer 
supplemented with protease inhibitors. Cell lysates were analyzed by western blot. 
 
RT-qPCR analysis 
Total RNA was extracted from cell pellets using the RNeasy Mini Kit (Qiagen). 
Quantitative RT-PCR was performed using iTaq Universal probes 1-step kit (Biorad) 
or iTaq Universal SYBR Green 1-step kit (Biorad) on a Bio-Rad CFX machine, and 
gene expression was normalized to the β-actin expression level. Taqman gene 
expression assays (RIPK1 and β-actin) were purchased from Thermofisher Scientific. 
 118 
DENV primers were purchased from Integrated DNA Technology (IDT) and RT-qPCR 
was performed. Thermocycler protocol for PCR reactions was; 40 cycles of 10 min at 
50°C, 3 min at 95°C, 15 sec at 95°C and 30 sec at 60°C. Similar concentrations of 
total RNA were compared to detect relative DENV RNA in cell lysates based on a 
standard curve calculated using primers for DENV2 (40).  
 
DENV plaque assay 
Virus titers were determined by immunostained plaque assay on Vero cells as 
described in (25). First, serial 0.5 log dilutions of virus-containing supernatants were 
added to Vero cells in a 96-well plate. After 2 hrs of incubation, overlay media 
containing MEM and 2% carboxymethyl cellulose was added to restrict viral spread. 
After 3 d, viral plaques were detected using anti-Dengue virus complex antibody 
(MAB 8705, Millipore Sigma) followed by the secondary antibody, mIgH-HRP (9060-
01, Southern Biotech). Spots were developed by the addition of the substrate solution 
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Activation of innate immunity due to the detection of viral replication products 
in the cell leads to the expression of hundreds of antiviral genes and proinflammatory 
cytokines and chemokines that control the spread of the infection. Because of this 
pivotal role in antiviral host defense, innate immune pathways are often targeted for 
inhibition by viruses. As summarized in Chapter 2, several viral proteins, including 
viral proteases, have been reported to modulate immune responses, allowing diverse 
families of viruses to modify the intra and extra-cellular environment to promote 
optimal conditions for replication and spread.  
Here we have found that DENV significantly decreased RIPK1 protein levels 
in infected cells. Overexpression of the DENV protease, NS2B3, was sufficient to 
decrease RIPK1 levels demonstrating a direct role for NS3 in RIPK1 reduction. NS3 
protease activity was fundamental for this effect, because the overexpression of a 
catalytically inactive protease mutant (NS2B3-S135A) did not result in a significant 
RIPK1 reduction. Additionally, both WT and protease mutant NS3 physically 
interacted with RIPK1. Furthermore, DENV inhibited NF-kB activation downstream 
of TNFR1 and TLR3 receptors by targeting RIPK1. Moreover, we detected DENV did 
not induce necroptosis and further suppressed T/S/Z-induced necroptosis in U937-DC-
SIGN cells. DENV infection did not induce proteasomal/lysosomal degradation of 




Implications of inhibition of RIPK1 signaling in DENV infection 
RIPK1 is placed at a crucial point in controlling cell death and inflammation. 
RIPK1-mediated signaling governs the outcome of signaling pathways initiated by 
TNFR1, TLR3, TLR4 and RIG-I/MDA5. RIPK1 is involved in signaling for NF-kB 
activation, MAPK and IRF3/7 phosphorylation. NF-kB induces pro-apoptotic genes as 
well as pro-inflammatory cytokines and chemokines that are important for signaling 
other immune cells. MAPK signals for AP-1 transcription, which induces the 
expression of several important cytokines. IFN responses are critical for restricting 
viral replication. IFNs further signal for the induction of hundreds of antiviral genes 
via the JAK/STAT pathway. Apart from these outcomes, RIPK1 signaling is 
implicated in several cell death mechanisms. RIPK1 is involved in driving extrinsic 
apoptosis or necroptosis downstream of TNFR1, TLR3 and TLR4. Since all the above-
mentioned strategies act as anti-viral mechanisms, RIPK1 has emerged as an attractive 
target for inhibition by viruses. This is exemplified by the breadth of RIPK1 inhibition 
strategies that have evolved in numerous viruses. For example, HIV-1 and HRV-16 
proteases cleave RIPK1 (1,2). Human HSV-1 proteins ICP6 and ICP10, MCMV M45 
protein, EBV LMP1 protein, and HTLV-1Tax protein all block protein-protein 
interactions of RIPK1 in signaling pathways by competitively binding to RIPK1 (3–6). 
Additionally, HSV-1 ICP6 and MCMV M45 selectively degrade RIPK1 via the 
autophagosome machinery (7). Furthermore, EBOV encodes miRNA that targets 
RIPK1 and decreases its transcript levels (8).  RIPK1 kinase-inactive mice exhibited 
increased viral titers following ZIKV and VACV infection while displaying increased 
susceptibility to WNV infection (9–11). These data indicate the importance of RIPK1 
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inhibition in virus infections. 
DENV stimulates immune responses via TLR7, TLR3, MDA5 and RIG-I. 
DENV NS1 is known to stimulate TLR4 (12–14). These stimulations result in the 
secretion of IFN-a/b that renders other host cells resistant to subsequent DENV 
infections (15). The secretion of TNFa during DENV infection results in the 
stimulation of TNFR1. TNFa stimulation results in the activation of dendritic cells 
leading to increased expression of cell surface costimulatory and activation molecules  
and enhancement of their antigen-presenting function (16–18). However, DENV has 
been reported to block the activation of infected dendritic cells, which may reduce 
priming of CD4+ or CD8+ T cells. Interestingly, non-infected bystander monocytes 
and dendritic cells still can become activated during DENV infection (19).  Gene 
expression analysis of acute dengue patients revealed lower levels of expression of 
genes associated with antigen processing, antigen presentation and T cell activation in 
DHF than in DF (20). Since RIPK1 is involved in TNFa signaling, we can speculate 
that inhibition of RIPK1 by DENV may decrease dendritic cell activation and 
maturation. Consequently, impaired antigen presentation and functionality of DENV-
infected DCs may reflect a viral evasion strategy to impede host immune responses. 
DENV infection was shown to block NF-𝛋B activation downstream of TLR3 
signaling, resulting in downregulated cytokine production (21). However, the 
mechanism by which DENV caused these altered responses had not been defined. 
Here, we demonstrated that DENV infection diminished NF-𝛋B activation in response 
to poly I:C stimulation by targeting and decreasing RIPK1 levels downstream of 
TLR3. The effect of the impairment of this pathway on IFN production, apoptosis and 
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necroptosis should be further investigated. 
There is evidence of the importance of RIPK1 function in T and B cells as 
well. For example, robust cross-priming of CD8+ T cells required intact RIPK1 
signaling and NF-kB-induced transcription in dying cells (22). Another study found a 
kinase-independent function of RIPK1 that is important for mature T-cell survival and 
proliferation (23).  RIPK1 function is also reported to be critical in B cell 
development; TLR4-stimulated RIPK1-/- B cells exhibited impaired NF- κB activation 
(24). Therefore, DENV-mediated inhibition of RIPK1 in T and B cells may play a role 
in altering critical immune pathways in these cells. Expanding our assays to study T 
and B cells may help decipher additional important roles of RIPK1-mediated signaling 
in DENV infection. 
RIPK1 is involved in type I IFN production downstream of the RIG-I/MDA-5 
pathway. Even though some studies could not detect a direct role of RIPK1 in IFNb 
production, we were able to detect a convincing positive effect of RIPK1 
overexpression on phosphorylation of IRF3 by western blotting. Additionally, we 
detected increased IFNb transcript levels with overexpression of RIPK1. These 
preliminary findings suggest a positive effect of RIPK1 on type I IFN production 
which is known to directly downregulate viral replication. Thus, RIPK1 inhibition 
becomes extremely advantageous for DENV. Further studies could be carried out to 
test if DENV-mediated RIPK1 inhibition contributes to downregulated type I IFNs 
downstream of RIG-I/MDA5. However, even though it is not the primary route, NF-
kB also induces IFNb and IFNg (25–28). Thus, further investigations are needed to 
understand if DENV inhibits the secretion of IFNb and IFNg by inhibiting NF-kB 
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pathway downstream of TNFR1 and TLR3. 
 
Apoptosis in DENV infection 
Liver injury is a common finding in DENV infection and can lead to organ 
failure. Apoptosis of hepatocytes following DENV infection is believed to contribute 
to this phenomenon (29). Apoptotic cells have been found in the liver, brain and lung 
tissues from autopsy examinations of DHF and DSS patients (30). The mechanisms by 
which DENV induces apoptosis are not known and may differ between different cell 
types. Recent findings show a protective role of RIPK1 against TNFɑ-mediated 
apoptosis in hepatocytes (31,32). RIPK1 knockout mice showed enhanced sensitivity 
to TNFα-mediated apoptosis and inflammation. The induction of NF-𝛋B target gene 
transcripts was also suppressed in these mice. Therefore, we speculate that the loss of 
RIPK1 during DENV infection may sensitize hepatocytes to cell death and 
inflammation, which could contribute to liver injury in DHF. 
 
Necroptosis in DENV infection 
Since viruses rely on the host cell machinery to propagate, host cell death is 
detrimental for viruses. Necroptosis is emerging as an important anti-viral mechanism 
for restricting viral replication. Apart from restricting viral propagation by destroying 
the cell, necroptosis is implicated in releasing intracellular DAMPs and PAMPs and 
promoting inflammation (33). RIPK1 kinase activity is important for necroptosis 
induction. Therefore, viruses target RIPK1 for inhibiting necroptosis. There is 
evidence that CMV, EBV and HIV-1 viruses inhibit necroptosis by targeting RIPK1 
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using various mechanisms as shown in Fig 3 of chapter 2.  We observed that 
necroptosis was not induced in vitro upon DENV infection. Furthermore, DENV was 
able to suppress artificially induced necroptosis downstream of TNFRI, possibly due 
to low levels of RIPK1. However, whether DENV stimulation of TLR3/4 leads to 
necroptosis is still unknown. Further efforts should address if necroptosis downstream 
of TLR3/4 contributes to dengue disease pathogenesis. 
 
The effect of RIPK1 on DENV replication 
There is evidence supporting a direct correlation between peak viremia titer 
and dengue disease severity (34) suggesting that efficient viral replication contributes 
to dengue disease. Staining for DENV structural proteins and viral RNA in human 
autopsies from dengue patients confirmed viral replication in lymph nodes, spleen, 
lung and liver (19). This excessive viral replication reflects the capability of DENV to 
suppress innate immune mechanisms efficiently. Thus, inhibition of RIPK1-mediated 
signaling, may also benefit DENV replication. 
Contrary to our expectations, we did not observe decreased intracellular viral 
RNA or infectious viral titers in the supernatants of cells when RIPK1 was 
overexpressed. Similarly, studies did not indicate a significant increase in intracellular 
viral RNA when endogenous RIPK1 was knocked down. Taken together, our 
observations do not support a direct link of RIPK1 levels affecting DENV replication. 
However, these experiments were done without stimulating the TNFR1. Thus, the 
effect of TNFa-induced NF-kB activation on DENV replication should be further 
investigated. For this purpose, relative intracellular viral RNA and infectious viral 
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titers in the supernatants of cells could be analyzed with overexpression of RIPK1 in 
the presence or absence of TNFa stimulation. Furthermore, the cytokines expressed by 
the induction of NF-kB could be more important for setting an antiviral state in the 
intact tissue/organism by activating uninfected bystander cells and T and B cells. This 
effect is hard to achieve in cell culture. Also, some of the cell lines we used may not 
effectively secrete inflammatory cytokines. Thus, it would be plausible to use PBMC 
from patients for testing the effect of RIPK1 on viral replication. Expanding our 
findings using human dendritic cell subsets isolated from blood or tissues will be 
important to characterize the full spectrum of immune responses mediated by RIPK1 
in DENV infection. 
 
DENV strain-specific effects on RIPK1  
Western blot results following infections with different strains of DENV revealed 
strain-specific effects on RIPK1 levels.  DENV1 strain Hawaii, DENV2 strain 16681, 
and DENV2 strain NGC exhibited a significant decrease in RIPK1 levels in Huh7 
cells. DENV1 strain C0245/96, DENV3 strain CH53489, and DENV3 strain 
C0360/96 displayed decreased RIPK1 levels, but this was not statistically significant. 
Interestingly, neither DENV4 strain 814669 nor H241 decreased RIPK1 significantly. 
These differences in effects on RIPK1 could be attributed to structural differences in 
the DENV protease complex, NS2B3. Crystal structure analysis of DENV protease 
complexes of DENV1, DENV2 and DENV4 revealed serotype-specific differences 
(35–37). Differences in substrate binding and substrate catalysis have also been 
attributed to structural differences between DENV proteases (35). Conformational 
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changes undergone by NS2B upon substrate binding account for additional variation. 
Differences in virulence in naturally circulating DENV strains and serotypes are 
speculated to contribute to dengue disease. For example, a study done on children with 
acute DENV infections reported secondary DENV2 caused more severe disease than 
DENV1 or DENV4, suggesting that virus genotype affects outcome (34). Altogether, 
our data indicate DENV strain-specific effects on RIPK1 reduction which could be 
responsible for differences in virulence exhibited by virus strains. 
  
Limitations and future experiments 
One limitation that was encountered in the study was the lack of availability of 
some commercial antibodies. None of the antibodies used could detect a cleaved 
product of RIPK1. Therefore, we concluded that the resulting fragment may be too 
small to detect by western blotting or may be further degraded. However, the exact 
mechanism of NS3-mediated cleavage/degradation of RIPK1 remains to be elucidated. 
We could not find a commercial antibody that could detect pro and cleaved caspase 8 
efficiently. Because of this, understanding the role of RIPK1 in caspase 8 activation 
was limited. 
Our studies were primarily done on immortalized cell lines and monocyte-
derived dendritic cells. There are some caveats in using cell lines for understanding 
intricate biological signaling pathways.  Generally, our findings are limited to one cell 
type, in cell culture, whereas many cells orchestrate to contribute to the outcome of 
infection in vivo. Even though some cell lines have intact NF-kB signaling, they may 
not secrete cytokines efficiently. RIPK1 signaling is regulated by cell-intrinsic as well 
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as cell-extrinsic stimuli. Extra-cellular stimuli under natural conditions would be better 
reflected in in vivo models. Therefore, our study could be extended to PBMCs and 
include the investigation of the effects of NF-kB inhibition on cytokine secretion in 
infected as well as bystander cells. Similar studies have been done to investigate the 
effect of RIPK1 inhibition in other diseases. For example, qRT-PCR analysis of 
peripheral blood leukocytes from patients with Systemic Lupus Erythematosus 
revealed lower RIPK1 transcript levels than from healthy individuals. Serum TNFa 
and IL-2 levels were also significantly lower in the SLE patients than in the healthy 
individuals (38). 
Additionally, it could be of interest to study the effect of “ADE” on RIPK1 
inhibition and cytokine expression by DENV. This could be achieved by infection of 
cells in the presence of cross-reactive DENV antibodies. Furthermore, it would be 
interesting to see in vivo effects of RIPK1 inhibition on DENV at an organismal level. 
However, DENV fails to antagonize mouse immune responses. WT mice usually do 
not sustain DENV replication or develop disease symptoms as seen in DHF (15,40). 
Therefore, understanding immune evasion strategies and the disease pathogenesis of 
DENV has been mostly limited to in vitro and ex vivo assays.  
We observed a physical interaction between RIPK1 and DENV NS3. However, 
we do not know what motifs of both proteins are important for this interaction. RIPK1 
is known to interact with other RHIM domain-containing proteins. Some viral proteins 
are known to contain RHIM-like domains. To investigate important motifs for this 
interaction, co-immunoprecipitation studies could be done with overexpression of 
DENV NS2B3 and RHIM-mutant RIPK1 plasmid. Furthermore, we do not know if 
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any other proteins are involved in the RIPK1-NS3 complex. For example, DENV NS5 
is known to interact with STAT2 and proteins of the ubiquitination machinery, 
resulting in STAT2 ubiquitination and degradation (41). Given that RIPK1 is post-
translationally modified by ubiquitination (42), the involvement of other proteins in 
the NS3-RIPK1 complex can be speculated. Mass spectrometry and proteomics 
analysis could reveal such complex formation during DENV infection. MCMV and 
HSV-1 viral proteins contain “IPAM” motifs that induce protein aggregates. RIPK1 
was shown to aggregate and get degraded in the presence of MCMV M45 protein and 
HSV-1 ICP6 protein. Such effects have not been tested in DENV so far. Therefore, it 
would be interesting to check if DENV could induce host proteins to aggregate 
including RIPK1. 
Additionally, the effect of RIPK1 inhibition on uninfected bystander cells 
should be investigated. Since RIPK1 inhibition leads to less cytokine secretion and 
inhibition of necroptosis, we can speculate that fewer bystander cells would be 
stimulated/activated, rendering them susceptible to DENV infection. 
There is evidence of a link between dysregulation of RIPK1 and the 
pathogenesis of inflammatory and neurogenerative diseases such as multiple sclerosis 
(MS), ALS, Alzheimer’s disease and inflammatory bowel disease (43). RIPK1 is 
emerging as a promising therapeutic target for treating such diseases. DENV infection 
in patients with such pre-existing conditions may be more likely to result in severe 
dengue disease due to further inhibition of RIPK1-mediated signaling. Thus, 
understanding the inhibition of RIPK1 signaling in viral disease pathogenesis will be 
helpful in treating other diseases as well. 
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Additional in silico analyses could be performed to investigate various aspects 
of NS3-RIPK1 interaction. DENV protease is known to recognize and cleave substrate 
sequences having a small amino acid following two basic residues (44, 45). A manual 
homology search for such sequences in RIPK1 could be carried out using 
bioinformatic tools such as DNASTAR Laser gene software. Site directed mutagenesis 
could be performed to mutate putative cleavage sites on RIPK1 experimentally. 
Further co-transfection experiments could be performed using DENV NS2B3 and 
plasmids encoding mutated RIPK1, which will be helpful for verifying if DENV NS3 
cleaves RIPK1.  
Viral proteins are known to interact with RIPK1 via RHIM domains. For 
example, CMV M45 protein interacts with RIPK1 via the RHIM domain. 
Furthermore, CMV M45 and HSV-1 ICP6 proteins induce RIPK1 aggregation and 
degradation via IPAM motif. Therefore, it would be interesting to investigate if such 
motifs exist in DENV NS3. Therefore, in silico analyses such as sequence 
comparisons and homology search for RHIM and IPAM motifs could be done. These 
analyses will potentially uncover DENV NS3 interactions between other RHIM 
containing host proteins such as TRIF 
In summary, this research has identified RIPK1 as a novel target of DENV 
NS3. These findings expand the knowledge of strategies used by DENV to evade 
innate immune responses. Manipulation of host cell RIPK1 by DENV may contribute 




Figure 1. Model 1: Cell-intrinsic effects of RIPK1 inhibition by DENV. DENV 
NS3 protein interacts with and decreases RIPK1 levels. TNFR1- and TLR3-stimulated 
NF-kB activation is impaired due to the NS3-mediated RIPK1 reduction. This may 
result in the downregulation of many antiviral genes resulting in decreased production 
of cytokines and chemokines. Cell death downstream of TNFR1 is also blocked by 
DENV due to decreased RIPK1 levels. This may result in increased cell survival 
allowing more efficient viral replication. The inhibition of necroptosis may also 





Figure 2. Model II: The effects of RIPK1 inhibition at a tissue/organism level. 
Inhibition of NF-kB activation by DENV may result in downregulated 
cytokine/chemokine/IFN secretion. Inhibition of necroptosis may result in cell 
survival, benefiting viral replication. These effects may result in increased virus 
production. Bystander cell activation and recruitment of T and B cells may be 
negatively affected by the inefficient cytokine/chemokine production. Uninfected cells 
could become susceptible to further infection by DENV. Therefore, controlling virus 
infection may be unsuccessful. The virus may spread into other cells/tissues/organs. 
Taken together, increased viremia and altered immune responses may contribute to 
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